,
the
</s>
.
of
and
)
in
(
to
was
a
were
with
for
The
%
by
at
that
is
as
on
from
patients
study
or
plasma
dose
after
be
;
1
an
drug
concentrations
In
2
administration
not
mg
concentration
using
this
]
than
=
[
h
are
pharmacokinetic
:
treatment
time
between
oral
model
3
pharmacokinetics
A
+
data
which
respectively
used
10
4
levels
observed
5
blood
studies
subjects
mean
clearance
samples
effect
days
compared
no
doses
group
analysis
/-
parameters
rats
both
mg/kg
This
all
had
significant
min
higher
two
results
its
clinical
administered
each
values
have
also
method
effects
significantly
PK
during
increased
rate
single
phase
dosing
serum
may
these
activity
6
hours
showed
day
has
total
following
but
under
±
been
healthy
into
C
bioavailability
<
human
other
20
range
absorption
exposure
Cmax
determined
}
distribution
24
acid
performed
groups
vivo
different
more
AUC
lower
one
30
12
high
three
Table
liver
obtained
when
elimination
mice
renal
similar
can
within
reported
it
received
cells
100
first
over
50
we
8
well
Figure
increase
intravenous
found
could
half-life
measured
vitro
P
standard
°
>
curve
only
body
patient
15
et
drugs
efficacy
infusion
based
those
area
shown
response
volume
daily
weight
injection
We
their
However
formulation
ratio
level
period
did
safety
rat
These
tissue
n
evaluated
differences
low
calculated
control
7
For
therapy
collected
peak
population
weeks
treated
maximum
urine
due
given
before
volunteers
solution
All
use
–
cell
tumor
metabolism
less
To
After
age
potential
test
toxicity
×
combination
most
cancer
disease
developed
release
metabolites
liquid
decreased
function
included
who
baseline
p
brain
per
protein
system
normal
water
there
any
years
then
our
value
further
times
sample
profile
90
including
present
same
described
such
without
metabolite
adverse
approximately
therapeutic
25
mass
demonstrated
changes
associated
difference
reduced
addition
ng/mL
assay
median
up
0.5
There
al.
studied
size
hepatic
profiles
active
formulations
greater
40
male
binding
models
No
assessed
determine
Fig.
while
either
inhibition
placebo
60
14
estimated
through
investigated
g
children
multiple
conducted
followed
It
events
trial
B
variability
Plasma
animals
inhibitor
versus
mL
free
systemic
relative
0.05
linear
previously
least
considered
0
I
excretion
against
analyzed
prepared
four
conditions
200
compounds
prior
pH
containing
HPLC
randomized
grade
via
new
USA
number
i.v.
decrease
compound
As
dosage
small
concentration-time
target
minutes
Pharmacokinetic
h.
Pharmacokinetics
chromatography
months
state
interaction
tissues
would
receiving
should
evaluate
reduction
because
dogs
achieved
delivery
properties
indicated
every
orally
regimen
related
rapid
CI
about
effective
uptake
interval
change
tolerated
95
according
out
alone
9
16
's
18
individual
major
AEs
previous
suggest
detected
48
receptor
development
®
IV
flow
available
will
apparent
II
disposition
validated
relationship
determination
evaluation
six
novel
if
resulted
temperature
stability
column
whereas
humans
clinically
tablets
above
predicted
At
applied
correlation
ratios
tested
0.1
required
11
stable
week
limit
80
detection
primary
findings
consistent
lung
initial
kidney
Patients
expression
acute
presence
ng/ml
mm
vs.
SD
average
solid
constant
occurred
nm
sampling
result
various
metabolic
order
final
monitoring
extraction
good
added
comparison
Blood
subject
amount
reference
design
important
tablet
taken
21
kinetics
methods
additional
28
Therefore
severe
influence
provided
spectrometry
assess
urinary
fluid
where
factor
approach
being
some
until
parameter
tumors
specific
insulin
analyses
once
recovery
rapidly
pharmacodynamic
t1/2
13
agent
cycle
women
five
very
precision
Although
internal
points
curves
μL
they
intestinal
characteristics
might
adult
end
An
rates
participants
sodium
accumulation
mouse
inhibitors
form
cohort
positive
x
however
400
statistically
animal
ranged
possible
comparable
improved
intervals
antibody
twice
CL
product
1.5
across
food
glucose
selected
accuracy
enrolled
500
regimens
set
duration
second
application
kg
impairment
identified
quantification
moderate
chronic
presented
terminal
risk
indicating
revealed
combined
injected
growth
among
reached
trials
infection
overall
heart
current
absorbed
experiments
last
steady-state
300
pressure
confirmed
provide
contrast
point
corresponding
female
highest
investigate
sensitive
known
increasing
performance
laboratory
dissolution
factors
m/z
expected
longer
17
vs
potent
limited
Tmax
experimental
’s
below
seen
indicate
large
adults
hr
criteria
ml
150
nanoparticles
37
Thus
steady
show
compartment
al
defined
mobile
resulting
increases
interactions
22
reaction
T
carried
trough
continuous
mild
exhibited
tolerability
2.5
site
type
mixture
radioactivity
i.e.
variation
examined
creatinine
whether
surface
Our
agents
impact
mg/m2
approved
On
assessment
crossover
suggesting
estimates
highly
IS
better
repeated
PD
species
suggested
several
part
pain
evidence
pharmacodynamics
case
relevant
advanced
fraction
skin
therefore
central
enzyme
treatments
recommended
prolonged
regression
250
0.01
Furthermore
best
19
objective
produced
preparation
solubility
likely
main
formation
1.0
failure
One
complete
percentage
although
route
responses
induced
common
confidence
Mean
enhanced
particle
MIC
affect
process
aqueous
plus
methanol
modeling
established
acetonitrile
and/or
software
When
extent
M
paclitaxel
bolus
protocol
1H
cycles
μg/mL
excreted
side
index
mM
cases
72
120
intravenously
gastrointestinal
measurements
information
relatively
35
early
role
medium
Phase
imaging
Day
75
rabbits
correlated
CYP3A4
improve
chemotherapy
transport
23
remained
peripheral
thus
survival
subcutaneous
36
Both
45
statistical
"
biological
mode
calibration
products
coefficient
tests
complex
high-performance
CSF
action
shows
matrix
ng
caused
selective
0.001
sensitivity
Clinical
circulation
mixed
maintained
buffer
hour
Chinese
aim
experienced
appropriate
does
version
characterized
liposomes
mechanism
0.2
“
26
ion
Based
Two
Following
much
intake
Hz
70
bone
pediatric
course
open-label
PBPK
molecular
affected
bioequivalence
whole
equivalent
means
content
unchanged
resistance
achieve
procedure
μg
generally
infections
even
stored
poor
m
gastric
d
inhibitory
morphine
'
”
expressed
negative
Japanese
here
geometric
successfully
error
suspension
China
proteins
breast
Moreover
surgery
conclusion
J
CA
lipid
C(max
29
support
antibodies
estimate
27
basis
analytes
absolute
toxicities
{
saline
32
fed
covariates
single-dose
optimal
unbound
derived
aged
induction
mL/min
sustained
retention
designed
enzymes
tacrolimus
compare
eight
signs
fixed
schedule
bile
slightly
physical
genotype
status
parent
extract
loading
purchased
variables
fasting
suggests
G
MTD
Drug
maximal
completed
v/v
fasted
covariate
except
simulated
t
measurement
ethanol
permeability
noted
efficiency
tract
analytical
acetate
screening
600
experiment
0.25
mg/L
monitored
tmax
μM
recorded
centrifuged
solutions
needed
s
extracted
membrane
half-lives
minimum
men
Group
elderly
concomitant
0.3
useful
throughout
midazolam
vancomycin
optimized
serious
made
room
dog
report
long
organs
independent
theophylline
predict
controls
subsequent
Subjects
immediately
-
individuals
larger
simple
mainly
With
weekly
Study
terms
chromatographic
NPs
published
incidence
investigation
appeared
exposures
*
University
albumin
research
demonstrate
cohorts
LC-MS/MS
cardiac
separated
preclinical
loss
ranging
prediction
ability
2.0
muscle
partial
safe
reduce
absence
involved
medication
deviation
1000
seven
ml/min
allowed
infants
antitumor
activities
intestine
reach
lead
consent
metabolized
since
consisted
monkeys
During
gene
Data
components
P-gp
need
conventional
measure
Supplementary
vein
neutropenia
Serum
33
direct
substrate
SC
short
controlled
line
assays
slow
fluorescence
dependent
r
describe
Each
P450
file
pathway
work
young
micrograms/ml
eliminated
digoxin
directly
suitable
affinity
μm
behavior
series
cytochrome
follows
gel
modified
males
post
symptoms
receive
incubated
Of
manner
score
31
equation
III
separation
significance
technique
inhibited
lack
divided
comparing
mg/day
dialysis
arm
variable
obtain
validation
guidelines
transplant
Further
pharmacological
frequency
CL/F
quality
periods
dissolved
many
gas
local
zero
general
still
penetration
necessary
count
promising
production
proposed
nM
blank
Inc.
excluded
5-FU
spleen
simulations
ionization
develop
antibiotic
C18
equal
alcohol
chemical
phosphate
collection
accordance
open
Overall
pulmonary
dose-dependent
later
organ
minimal
Using
together
QC
fast
two-compartment
rpm
starting
fit
almost
upon
Results
history
metformin
degree
tumour
half
double-blind
long-term
IC50
testing
injections
capsule
adjusted
sites
e.g.
CYP3A
improvement
another
adequate
structure
physiological
peptide
intramuscular
MTX
endogenous
quantitative
diluted
nausea
potency
provides
Because
LLOQ
acceptable
kinetic
so
CYP2D6
upper
literature
elevated
cause
antagonist
see
DNA
cellular
cisplatin
randomly
D
meal
consecutive
secondary
receptors
led
purpose
formic
outcome
predictive
V
isolated
observations
sex
tandem
estimation
L
summarized
capsules
Japan
reactions
amounts
42
condition
progression
calcium
’
especially
females
altered
targeting
mechanisms
forms
doxorubicin
incubation
procedures
Since
undergoing
outcomes
washout
potentially
34
informed
bacterial
PBS
≥
generated
maintenance
separate
removed
HIV
currently
intensity
tubes
0.4
docetaxel
areas
extensive
solvent
systems
percent
CYP
first-order
alternative
Three
1.2
examination
event
diabetes
assessments
strong
full
powder
oil
hydrochloride
cyclosporine
MA
supernatant
simultaneous
distributed
commonly
sufficient
vital
rifampicin
F
vehicle
particles
N
limits
virus
severity
majority
gradient
association
metastatic
MPA
feces
populations
activation
propofol
assigned
care
residence
recovered
ciprofloxacin
infusions
Animal
inclusion
PK/PD
mg/mL
future
simulation
Germany
$
nonlinear
diseases
identify
warfarin
prodrug
bound
indicates
cumulative
dosed
account
start
strategy
DLT
3.0
appears
routes
variance
milk
lines
able
coadministration
efflux
widely
taking
residual
pattern
96
platelet
secretion
2.1
pregnancy
micelles
smaller
organic
typical
peaks
biodistribution
analysed
recombinant
enantiomers
kg-1
quantitation
AE
clear
standards
rabbit
quantified
man
Safety
faster
probe
lowest
follow-up
arterial
carcinoma
rather
transplantation
tube
probably
displayed
Co.
light
PEG
delayed
proportion
CsA
caffeine
fitted
observation
remaining
concluded
characterize
Additionally
Committee
genetic
do
precipitation
adjustment
stage
preparations
inhibit
respect
38
reports
diet
visit
released
measures
third
pretreatment
CV
proportional
polymorphisms
recipients
relationships
differ
carboplatin
escalation
placed
detectable
having
Compared
mg/kg/day
types
strains
pathways
explained
accurate
PET
mg/m(2
medical
leading
Research
employed
gentamicin
respiratory
monotherapy
beta
Samples
particularly
attributed
diarrhea
morning
molecules
3.5
degradation
iv
linearity
sequence
While
material
neonates
volumes
sulfate
step
coefficients
slower
Finally
Oral
postdose
0.8
monoclonal
little
venous
microsomes
white
2H
primarily
onset
shorter
vitamin
µL
post-dose
despite
IR
circulating
scores
kinase
respective
Administration
derivatives
markedly
Treatment
L/h
S1
infinity
enhance
pigs
extended
nine
800
decreases
ANOVA
infected
capacity
counts
life
toxic
Ltd.
intracellular
suppression
include
If
pregnant
intact
microg
iron
minor
injury
CYP2C19
transferred
transporters
glucuronide
0.6
curcumin
omeprazole
class
kidneys
From
liposomal
fully
excellent
possibly
simultaneously
example
molecule
power
around
contained
overnight
them
7.4
39
delivered
component
anticancer
malaria
Effect
assumed
consisting
source
discontinued
often
μg/ml
allow
coupled
biliary
frequently
inter-day
mmol
fat
4.6
confirm
tolerance
vascular
alter
inflammatory
Then
R
represents
ECG
marrow
ranges
transporter
old
55
predictions
interest
done
showing
loaded
interindividual
agreement
impaired
BID
preliminary
medications
polymer
vomiting
MRT
nicotine
finding
cholesterol
synthesis
Fig
completely
placebo-controlled
evaluable
irinotecan
antibiotics
marked
filtration
dose-limiting
chosen
continued
formed
spiked
earlier
produce
wide
65
program
NONMEM
degrees
along
synthesized
fentanyl
nasal
conjugate
trend
hemodialysis
electrospray
43
once-daily
Institute
240
p.o.
explain
conjugates
exposed
benefit
few
diffusion
drawn
influenced
7.5
44
death
responsible
prospective
multiple-dose
0.9
particular
perfusion
s.c.
acids
ill
functional
BMI
barrier
bleeding
analyte
region
spectrometer
centrifugation
pure
aimed
Medical
intraperitoneal
plots
selectivity
recent
varied
subsequently
frequent
dynamic
occur
review
key
recently
co-administration
selection
targeted
i.p.
kg(-1
signal
compartments
K
ng/mL.
By
formula
0.02
CIs
41
phenytoin
Among
inhalation
IM
conversion
Click
hand
soluble
anesthesia
Total
ibuprofen
magnitude
culture
ER
fact
consumption
dysfunction
random
paracetamol
dispersion
hypertension
Agilent
nor
substrates
hormone
threshold
summary
dilution
acetaminophen
close
induce
base
next
TEAEs
gemcitabine
μl
ingestion
left
viral
Other
IgG
red
administrations
reducing
stomach
contribute
MS
regarding
log
appear
syndrome
run
images
Additional
180
decline
ammonium
practice
2000
reductions
clearances
genes
media
assayed
processes
underwent
nitrogen
declined
P.
obese
T1/2
Population
washed
peritoneal
Similarly
PTX
gender
verapamil
density
inflammation
5.0
discontinuation
phases
UK
derivative
\usepackage{amssymb
\usepackage{amsfonts
cytotoxicity
remains
diameter
Despite
cardiovascular
noncompartmental
Waters
horses
transdermal
treat
National
high-dose
efavirenz
purified
variations
identical
56
availability
yield
refractory
initiation
Vd
setting
hypothesis
endpoints
1.1
dried
superior
Only
ketoconazole
pump
4.5
fatigue
alpha
damage
Food
methotrexate
microspheres
genotypes
RNA
critical
kept
E
critically
commercial
gave
intrinsic
HCl
transfer
cocaine
month
comparisons
juice
chromatography-tandem
bacteria
gut
storage
agonist
substantial
lesions
unit
M1
characterization
125
dosages
amino
clearly
enhancement
elution
transient
prevent
4.0
fetal
topical
85
probability
immune
normalized
colon
\usepackage{amsbsy
\usepackage{amsmath
\usepackage{wasysym
\usepackage{mathrsfs
\usepackage{upgreek
\setlength{\oddsidemargin}{-69pt
monkey
older
Six
labeled
authors
visual
cleared
0.75
Sprague-Dawley
prostate
measuring
occurring
slowly
examine
µg/mL
1.7
ritonavir
Most
scale
ethyl
measurable
carriers
52
testosterone
require
maintain
ocular
predose
eye
NMR
propranolol
mediated
disorders
pooled
Analysis
health
46
FDA
hydrolysis
poorly
specificity
Grade
chain
courses
carbamazepine
Laboratory
chloride
H
parallel
establish
non-compartmental
favorable
bilirubin
unknown
lungs
modelling
They
1.8
Median
structural
L/kg
withdrawal
rectal
cortisol
Dose
represent
must
cimetidine
clopidogrel
GFR
markers
activated
Use
murine
reliable
mRNA
DOX
conjugated
bias
≤
Briefly
headache
leukemia
CNS
optimization
accounted
micrograms
diabetic
™
thrombocytopenia
calculate
marker
maternal
CYP2C9
UV
salt
lidocaine
natural
access
i.m.
first-pass
RA
1.3
Similar
Four
detector
Adverse
sheep
heparin
delay
glomerular
infused
i
LC
Animals
ensure
allele
Part
Evaluation
resistant
management
efficient
cats
PR
analgesic
targets
l
Statistical
importance
carrier
endpoint
candidate
eligible
ex
0.7
actual
determining
layer
changed
intra-
CYP1A2
polymorphism
substantially
one-compartment
P-glycoprotein
prophylaxis
coadministered
untreated
1.4
written
rifampin
Here
X
zeta
1.6
detect
conclude
dry
intranasal
cross-over
microg/ml
DLTs
knowledge
?
US
47
explored
anti-inflammatory
regions
contribution
54
CR
Scientific
stock
whom
permeation
hepatitis
diclofenac
hepatocytes
purity
Effects
mg/l
relation
investigator
variants
Peak
0.03
Emax
right
ALT
DHA
modification
→
QD
adequately
capillary
Cmin
paper
composition
subjected
AUCs
8)
term
inhaled
S.
platinum
dietary
Caucasian
utilized
ABCB1
original
rosuvastatin
ELISA
potassium
year
0.0001
exceeded
slope
cm
none
supported
glycol
reverse
m−2
nature
WinNonlin
routine
saturation
AT
Caco-2
ovarian
Hospital
compliance
microM
avoid
entire
combinations
itraconazole
block
therapies
opioid
plates
like
evaluating
residue
slight
length
sunitinib
malignancies
seems
VPA
wild-type
involving
incorporated
−
equations
ions
Concentrations
Human
possibility
cytotoxic
EE
furosemide
fluconazole
plate
artery
Care
space
tumours
effectively
Development
According
approaches
coli
recoveries
ppm
etoposide
dexamethasone
calculation
δ
nervous
understanding
functions
24-h
constants
met
New
Also
abdominal
SN-38
12.5
Bayesian
started
S2
pre-dose
C.
CYP3A5
Studies
surgical
sedation
aminotransferase
comparative
nearly
49
Bioavailability
drug-drug
onto
proved
bioequivalent
Center
certain
thereby
decreasing
BSA
way
extensively
QT
ester
µM
oxidative
tool
explore
1/2
NSCLC
extracellular
demonstrates
limitations
initially
Health
reason
scaling
radiation
‘
though
latter
unlikely
atorvastatin
Five
nifedipine
64
methadone
planned
fractions
serial
saliva
--
DDI
catheter
PFS
Due
represented
cirrhosis
mortality
help
fold
input
MRM
processed
requirements
traditional
beagle
quantify
pretreated
load
intensive
converted
R2
colorectal
meropenem
replacement
treating
ms
differential
randomised
energy
resolved
aureus
2.2
diazepam
corrected
biochemical
weighing
AUC0-∞
Corporation
oxycodone
apoptosis
microscopy
prednisolone
MS/MS
spray
inhibits
Shanghai
liposome
1:1
identification
physicochemical
requiring
1.25
challenge
subcutaneously
proliferation
effectiveness
essential
Cancer
varying
Comparison
dose-escalation
antigen
erlotinib
dopamine
2.4
vaginal
difficult
bevacizumab
resolution
alterations
SAS
allows
microdialysis
occurrence
scanning
SEM
variety
PLGA
objectives
Wistar
reasons
biotransformation
emulsion
prolongation
tuberculosis
reaching
ss
−20
working
strategies
MMF
&
schedules
endothelial
strongly
AUClast
how
Good
gavage
extracts
GI
investigations
occurs
kg/m2
evaluations
µg
weights
HCV
glucuronidation
pneumonia
correlations
hospital
kg−1
electron
synthetic
double
2013
equilibrium
HIV-1
yet
removal
withdrawn
frozen
numbers
57
again
arms
chemistry
physiologically
occupancy
United
antimicrobial
completion
pancreatic
2015
abnormalities
returned
device
ten
PO
statistics
failed
DMSO
formulated
diagnosis
smoking
elevation
leads
ligand
providing
isolates
regard
output
reflect
biomarkers
aggregation
composed
scan
2011
filtered
Model
coated
negligible
strain
International
encapsulation
BBB
date
tracer
regardless
AUC0–∞
underlying
metabolizers
2012
aspirin
ring
play
2010
moiety
techniques
b
intermediate
pharmacology
patterns
considerable
extrapolated
min-1
separately
melanoma
ether
tail
pronounced
emission
progressive
Several
Given
thereafter
filter
quercetin
Interestingly
complexes
antagonists
drug-related
Renal
Helsinki
2014
58
·
film
AUC0-t
lymphoma
MHz
E.
achieving
#
units
spectrum
Institutional
S
CBZ
oxidation
conjugation
robust
cerebrospinal
RSD
surfactant
51
retained
seizures
regular
concurrent
amikacin
CT
53
fitting
acquired
98
analogue
QTc
metoprolol
yielded
Thermo
medicine
recommendations
evident
usually
sustained-release
ESI
generic
participant
moxifloxacin
sorafenib
Declaration
documented
spectra
reversible
1.9
First
stress
adding
Hence
hydrophilic
methyl
phenomenon
signaling
constructed
Ethics
2.3
Fisher
BW
ml-1
co-administered
6.0
sets
accurately
successful
—
regulatory
voriconazole
simvastatin
detailed
variant
patch
malignant
exhibit
AUCinf
requires
structures
−80
xenograft
TB
AST
younger
staining
trastuzumab
PEGylated
lymph
advantage
prescribed
article
European
prevention
levodopa
make
peptides
toward
predicting
characteristic
antiviral
r2
lithium
epithelial
2.6
tubular
chemicals
breakfast
AD
1,000
cynomolgus
rise
basal
tramadol
adherence
pharmaceutical
µm
abnormal
core
lipophilic
demonstrating
trapezoidal
improving
encapsulated
magnetic
give
already
Rats
antibacterial
hemoglobin
fibrosis
99
depending
Days
meaningful
0.15
height
applications
considerably
MRI
EC50
treatment-related
63
efficacious
CYP2B6
2016
antiretroviral
demographic
mutations
Serial
exclusion
listed
predominantly
2.7
experience
stimulation
averaged
w/v
inhibiting
equipped
analog
6.8
beneficial
recruited
P<0.05
lag
affecting
protocols
3.2
0.04
reconstituted
Cl
High
portion
discussed
true
hrs
arthritis
TRUNCATED
generation
Healthy
warranted
basic
MICs
registered
optimize
b.i.d.
calves
immunodeficiency
67
Vss
WORDS
3H
HIV-infected
Determination
bearing
precise
OS
mucosa
evaporated
fusion
position
newly
fatty
Twelve
3A
beginning
substances
initiated
metastases
matched
balance
5.5
specifically
B.
shape
standardized
t-test
protease
exception
interference
sizes
unique
computed
assessing
2.8
Male
whose
microemulsion
84
fluids
deaths
recurrent
CD4
contents
representative
aliquot
appearance
multicenter
cerebral
external
additive
160
postoperative
fragment
24-hour
imatinib
nominal
parasite
weak
bovine
MO
2008
microg/mL
took
considering
remain
pathogens
substance
inter-individual
M2
ticagrelor
oxygen
quinidine
molar
Asian
Ten
triple
nanoparticle
clinic
sequential
cyclophosphamide
reduces
TFV
erythromycin
biomarker
rivaroxaban
topotecan
approval
Absorption
SNPs
sum
microsomal
developing
allometric
reviewed
transit
Pharmaceutical
mg/dL
attained
wavelength
risperidone
closely
GH
Sigma-Aldrich
short-term
disorder
h-1
dual
weighed
center
largely
distinct
antipyrine
neither
take
morphology
low-dose
diltiazem
fell
entry
towards
burden
causes
depression
Figures
Technologies
anesthetized
residues
6.5
cancers
exercise
racemic
mAb
IP
contains
obvious
intermittent
transitions
field
correlate
comprised
A.
classified
mostly
Previous
m2
great
differed
kDa
reflected
VEGF
disappearance
2009
h(-1
rule
spectroscopy
long-acting
participated
contributed
sections
immediate
citrate
Louis
errors
PCR
GA
asthma
62
59
Single
exhibits
examinations
describes
phenobarbital
undertaken
entrapment
450
linked
just
visits
partition
correction
protection
sampled
greatly
FVIII
mutation
marketed
quickly
utility
fever
PA
investigational
situ
biphasic
analgesia
enrofloxacin
falciparum
levofloxacin
commercially
PM
BP
entered
bioavailable
reversed-phase
hence
Significant
neutrophil
ongoing
myocardial
mg/ml
hydrophobic
applicable
66
perfused
sildenafil
adjustments
States
fecal
bid
ClinicalTrials.gov
parenteral
phenotype
processing
non-linear
EFV
pilot
background
adolescents
750
HR
h/mL
panel
AUC0–24
twice-daily
excess
bladder
2007
Maximum
seizure
relevance
spectrometric
Mice
insufficiency
rash
supplementation
features
susceptible
birth
understand
hematologic
1200
Another
easily
3.3
modest
MD
section
desired
emptying
alanine
amoxicillin
analyze
Compound
fresh
ventricular
Comparative
t½
assuming
8.0
plot
Tokyo
consideration
late
dataset
w/w
chitosan
motor
chamber
allowing
radiolabeled
viability
compartmental
facilitate
enrollment
61
M3
t(1/2
describing
3.6
instead
68
acetic
depletion
capecitabine
pneumoniae
feasible
71
kit
enzymatic
occasions
paediatric
wall
remission
partially
cavity
transition
tomography
Laboratories
TDM
g/kg
necrosis
max
aeruginosa
calculations
feasibility
coronary
environment
Nevertheless
eluted
linezolid
EGFR
vortexed
time-dependent
susceptibility
AA
Practice
Participants
intervention
gradually
Cohort
online
0.06
blockade
discovery
nude
liquid-liquid
episodes
replaced
3.1
water-soluble
Consequently
isoniazid
cultured
xenografts
NC
scheduled
readily
advantages
limiting
weighted
2006
Western
accumulated
estradiol
consistently
membranes
portal
modifications
intragastric
proportionality
analogues
quantifiable
concentrated
minute
More
Eight
distilled
ml/min/kg
amorphous
Urinary
bactericidal
epilepsy
far
broad
methodology
evening
tended
strength
immunogenicity
FA
ascending
Urine
diagnostic
ml(-1
tyrosine
herbal
implemented
now
\begin{document}$$
American
mmol/L
sacrificed
sepsis
back
expansion
ADA
integrated
similarly
AUC0–t
systolic
vitreous
screened
Subsequently
window
air
St.
abuse
option
Ltd
others
Its
polymeric
reasonable
voltage
bupivacaine
Carlo
acidic
Criteria
monitor
SR
Clearance
polyethylene
IU
green
peaked
78
implications
ie
Monte
modeled
Tissue
affects
near
BPA
passive
supplemented
tobramycin
typically
CPT-11
2A
sleep
Chromatographic
105
us
urea
beyond
limitation
UPLC-MS/MS
diagnosed
algorithm
0.08
resonance
plotted
intra-day
amlodipine
illustrated
CO2
choice
None
SMEDDS
macrophages
representing
nephrotoxicity
enough
CF
DTX
coating
2017
died
blocking
PS
analogs
exploratory
attainment
eyes
off
crystalline
Tween
deficiency
transmission
coagulation
rejection
neonatal
IQR
DSC
CS
2.9
ranitidine
ketamine
X-ray
supplied
Pharsight
Tumor
Shimadzu
5-fluorouracil
manufacturer
place
drop
ages
extremely
sirolimus
enhancing
SPSS
exponential
7.0
pg/mL
bioanalytical
Multiple
3.4
Secondary
blood-brain
2004
interstitial
168
83
goats
clarithromycin
stirred
nevirapine
ingested
.05
Some
UPLC
prepare
native
suppressed
pellets
introduced
hydrogen
replicates
complications
MR
global
CBD
acceptance
supplementary
volunteer
prodrugs
supports
glass
Cell
behavioral
minimize
humor
ceftazidime
synergistic
anticoagulant
define
inactive
satisfactory
ceftriaxone
reproducible
continuously
donor
note
ice
4.2
AUC(0-infinity
Sigma
microgram/ml
incorporation
image
goal
74
housed
Version
2005
stem
azithromycin
ad
olanzapine
India
NJ
Tables
charge
mmHg
Efficacy
overcome
states
73
dabigatran
0.005
become
2-fold
concerns
mg/liter
feeding
anemia
Review
tenofovir
3000
Baseline
gamma
V1
min(-1
perform
spinal
scans
rituximab
narrow
triplicate
HPMC
de
gain
details
everolimus
febrile
generate
high-fat
speed
AS
3.8
sources
Under
supporting
joint
individually
deviations
paired
became
simulate
homogenate
c
behaviour
System
soft
principles
retrospective
106
precursor
plays
carbon
mg/d
namely
institutional
lumefantrine
Differences
sequences
isocratic
equivalence
outside
Beijing
bind
specimens
half‐life
pulse
cent
ampicillin
unclear
thyroid
concomitantly
autosampler
explanation
jugular
C0
view
relapse
magnesium
needs
making
criterion
repeat
cord
zidovudine
distributions
pharmacologic
Chemical
head
saturable
EDTA
TEM
syringe
parts
too
ICU
find
antioxidant
batch
ART
3.7
lesion
apixaban
dependence
y
family
2002
Korean
nerve
4000
SA
label
76
5.2
WT
AUC0-24
ELF
busulfan
technology
probenecid
S3
µl
African
polymers
aspartate
0.99
69
10.0
ingredients
oxide
zinc
fashion
domain
settings
solid-phase
interpretation
protective
NaCl
extrapolation
benefits
2003
0.12
what
steps
stages
acquisition
committee
Km
mechanistic
always
lymphatic
77
Korea
sublingual
infant
Standard
specified
pig
alkaline
4.1
guinea
users
operated
unaffected
rest
decay
lipids
success
channel
grapefruit
drinking
LOQ
AG
oxaliplatin
0.45
cure
chromatography-mass
Intravenous
cyclosporin
ii
absorbance
meloxicam
escalating
bioactive
anticipated
6.3
indomethacin
relapsed
lymphocyte
purification
Staphylococcus
fluorescent
metronidazole
cortex
Such
FDC
quadrupole
baicalin
analyzing
Patient
greatest
theoretical
Supplemental
electrocardiogram
mentioned
Methods
82
bootstrap
linearly
3.9
M.
deposition
permitted
quantitatively
similarity
aliquots
tamoxifen
0.10
ASA
mellitus
mucosal
Millipore
AML
1A
indices
proximal
MPH
antiepileptic
L.
350
360
accepted
proven
HD
meals
T(max
RT
libitum
consequence
microscope
likelihood
itself
rhesus
verified
cm−1
stained
remove
Systemic
ESRD
attributable
nuclear
gestational
erythrocytes
92
LD
neutral
resveratrol
0.22
Student
race
smokers
precisions
PDI
PKs
bath
4.8
exceed
trends
assumption
h/ml
Seven
GraphPad
THC
exact
CD
investigators
mixtures
context
hoc
bupropion
Ctrough
14C
regional
raw
dose-response
prophylactic
adipose
7.2
94
enterohepatic
optimum
eGFR
transformed
Calibration
thought
solvents
900
4.4
dialysate
San
81
suspected
µg/ml
materials
110
down
96-well
problems
mutant
Influence
immunoassay
lymphocytes
randomization
anti-tumor
piperacillin
nmol/L
clozapine
predetermined
Control
hematology
dose-proportional
2B
Approximately
descriptive
chiral
treatment-emergent
97
radioactive
THIS
capable
valuable
memory
served
IIV
Information
chromatograms
insufficient
administrated
88
GMR
existing
Individual
problem
heparinized
Cycle
OR
Elimination
BA
reagents
cytokine
fluoxetine
buprenorphine
86
ideal
chloroquine
rodent
79
surrogate
l/kg
dermal
dizziness
probes
Changes
accompanied
binds
spherical
maintaining
Considering
Assessment
Cells
cocktail
lactate
France
fall
28-day
administering
CDDP
reagent
lasting
10-fold
sterile
ULN
accelerated
session
87
log-transformed
radioimmunoassay
otherwise
homozygous
premature
indication
plateau
subjective
GSH
agonists
epinephrine
unconjugated
ethics
owing
IL-6
mixing
140
undetectable
hematological
vesicles
genistein
unrelated
Software
matrices
modulation
vary
urinalysis
antifungal
preferred
pharmacokinetic/pharmacodynamic
hydroxylation
1500
Prior
guidance
competitive
reversed
Indeed
extension
cultures
influences
berberine
killing
IN
consumed
predictor
API
diarrhoea
2001
8.5
phosphorylation
requirement
TAC
lamivudine
93
missing
AZT
dd
attention
predominant
PK-PD
Medicine
involvement
collision
tumor-bearing
scheme
postprandial
ethical
safely
dose-related
alleles
rheumatoid
empirical
Common
anticonvulsant
fragments
hypothesized
EM
persistent
Before
fourth
tendency
excipients
subset
PB
FcRn
artesunate
oseltamivir
91
participation
diastolic
Protein
pass
two-way
mL/kg
seem
4.3
GLP-1
hypertensive
exchange
mixed-effects
combining
blinded
guide
Ki
validate
moderately
undergo
anaesthesia
focused
exogenous
causing
neuropathy
biopsies
Republic
CP
OFV
principal
utilizing
OA
Within
check
Disposition
database
middle
SAEs
Response
homogenates
feed
efficiently
Merck
Simultaneous
shock
buccal
Twenty
quite
penicillin
practical
Time
apart
follow
enantiomer
first-line
CAS
glutathione
well-tolerated
intended
0.07
SE
3A4
ultraviolet
depot
ribavirin
swelling
issues
signals
RECIST
mV
ml−1
BD
Canada
fractional
serve
preterm
skeletal
incorporating
computer
valproate
withdrew
synovial
constituents
flux
equally
induces
extended-release
0.17
faeces
silica
deliver
frequencies
titration
Board
lowering
MET
Parkinson
schizophrenia
rodents
turnover
graft
ofloxacin
mononuclear
6.4
5.3
stirring
fewer
pool
Pharmacodynamic
LC-MS
deemed
seconds
consider
cognitive
Vmax
Taken
89
SNEDDS
concern
mefloquine
dissociation
concentration-dependent
pharmacologically
positively
Children
4.7
celecoxib
includes
aspects
5.6
E2
humidity
ml/kg
cold
exist
admitted
improvements
isoflurane
dehydrogenase
nanosuspension
cytokines
partly
dark
enable
property
unexpected
10,000
square
stopped
log10
hypersensitivity
μg/kg
lipophilicity
postmenopausal
aims
BCRP
dryness
naproxen
\documentclass[12pt]{minimal
granules
AUC∞
post-treatment
spontaneous
harvested
alteration
timing
ivermectin
0.33
quinine
valproic
α
acyclovir
contraceptive
serotonin
immunosuppressive
squares
progesterone
interpatient
CYP2C8
vacuum
7-day
1B
Phoenix
haloperidol
address
invasive
dispersed
evaporation
Nine
PMs
OC
platform
indinavir
prescription
Technology
Steady-state
maturation
0.09
two-period
Sciences
laser
Css
posaconazole
PQ
dynamics
colistin
7.3
MTT
hemodynamic
Scale
ng/g
Exposure
bond
v
deep
mAbs
forward
countries
reproducibility
MDR1
3D
chemotherapeutic
quantity
complicated
Consistent
ropivacaine
meet
bodyweight
three-compartment
hair
largest
homogenized
past
Trial
ID
people
investigating
puerarin
paroxetine
estimating
admission
diminished
hydrogel
systematic
implanted
esomeprazole
0.13
cellulose
demographics
subgroup
applying
Simulations
viable
suspensions
twofold
FEV1
stepwise
dexmedetomidine
confirming
expressing
2a
doxycycline
restricted
biopsy
capture
producing
ECGs
lipoprotein
0.11
PE
shift
130
☑
gefitinib
Therapeutic
prednisone
net
candidates
reabsorption
1b
edema
QTcF
accounting
indirect
Importantly
480
cross
reflecting
Netherlands
AM
brief
1a
μmol/L
obesity
0.002
Eq.
0.16
0.14
nmol
needle
offer
seemed
5.4
Ka
Hg
epidural
stratified
ligands
ethnic
losartan
overdose
Q
LH
substitution
104
mycophenolate
Fc
supplement
gabapentin
one-way
essentially
6.2
Oncology
operating
INH
ketoprofen
PC
instrument
involves
Cremophor
viscosity
regulation
usual
charcoal
infliximab
Sprague
negatively
organisms
batches
responders
antidepressant
SLNs
integrity
cost
interfere
LC/MS/MS
comprising
suspended
Their
histological
mechanical
radiotherapy
multidrug
atenolol
CKD
glioma
Solid
TDF
bowel
incomplete
reveal
sparse
fungal
bypass
antimalarial
0.50
canine
microparticles
fluvoxamine
participating
melatonin
4.9
Doses
Body
elucidate
U
Bioequivalence
concept
contact
elevations
5000
makes
tolerable
uniform
package
C2
hepatotoxicity
Dawley
saturated
β
Application
phosphatase
table
NP
stroke
amiodarone
alfentanil
independently
FF
inducer
labeling
silico
percentages
actions
μg/mL.
Area
Prism
depends
presents
symptomatic
circadian
neurological
Disease
vials
located
description
RBC
alfa
COPD
AP
cattle
alkaloids
Neither
haemodialysis
144
6.1
manuscript
lactone
isomers
reductase
acting
Experimental
crushed
irradiation
mL(-1
dose-normalized
LOD
.001
transformation
Next
1.00
Eligible
8.3
contain
Metabolism
evidenced
Accordingly
reflects
exceeding
Recently
produces
5.1
judged
Pt
injectable
figure
p<0.05
EEG
ginsenoside
accumulate
comprehensive
blocked
DCE-MRI
bromide
OATP1B1
cervical
interday
PPK
Relative
improves
associations
WHAT
raised
Pharmaceuticals
Sample
child
T2DM
interferon
neurotoxicity
cefazolin
lesser
Type
DA
3B
intraperitoneally
preventing
Higher
reporting
BAY
logistic
locally
6.6
folate
Second
NY
DDIs
predefined
high-pressure
purposes
MDI
HA
NS
diffraction
lamotrigine
gelatin
composite
inserted
cessation
Phenomenex
fate
Preclinical
AB
platelets
AL
pravastatin
IL
≥3
neck
cutoff
immediate-release
valsartan
metastasis
anesthetic
12-lead
profiling
normally
tolbutamide
amide
heated
selectively
uncertainty
mycophenolic
cefepime
TNF-α
RTV
illness
aripiprazole
supplements
thickness
disappeared
mathematical
intravitreal
City
Inhibition
transaminase
prolong
South
giving
relief
interface
flavonoids
PI
Even
sufficiently
0.20
crucial
Coadministration
LTG
allocated
ORR
individualized
automated
Different
steroid
physiologic
consequently
offers
instructions
M6
livers
interesting
predictors
conclusions
3/4
prospectively
ICG
decision
Twenty-four
7.8
myelosuppression
thrombin
Escherichia
4A
crude
beads
vessels
humanized
Quantitative
balanced
pathological
whole-body
posterior
exists
2C
INR
ka
PVP
HPLC-MS/MS
hematopoietic
nanoemulsion
Aβ
instillation
charged
inducers
inducing
prevented
lansoprazole
6.7
multivariate
drying
special
CrCl
single-agent
~
Da
levetiracetam
adenocarcinoma
7.6
RE
carefully
black
Detection
Pseudomonas
cystic
handling
AC
SLCO1B1
S-1
AUC(0-t
pancreas
enhances
H.
progression-free
stereoselective
artemether
dihydroartemisinin
CLCR
WHO
Cary
Acute
Vc
MAD
pharmacokinetic-pharmacodynamic
l/h
finally
salbutamol
select
indicator
metabolizing
Liver
VAS
conduct
single-center
TP
caution
8.2
temporal
labelled
lowered
adopted
rescue
AUC/MIC
behaviors
109
calculating
5.7
CRP
CC
determinations
0.80
RIF
corresponded
vinorelbine
intramuscularly
amphotericin
BI
rank
biologic
influencing
ileum
HCC
EC
somewhat
daptomycin
ECMO
participate
apparatus
mofetil
lyophilized
Milford
MBq
5.8
virtual
thermal
0.35
0.18
in-vitro
t(max
act
fish
fluoride
dosimetry
No.
LA
stronger
D3
dispersions
hematocrit
scaled
Notably
Inc
hypotension
rose
depicted
Toxicity
zero-order
BALB/c
Wilcoxon
promote
V2
pg/ml
continue
artemisinin
parasites
hybrid
escalated
gestation
angiogenesis
Meanwhile
Ktrans
mL−1
adjuvant
raltegravir
stabilized
classification
Mass
Hb
antihypertensive
AMG
ACE
MDZ
surfactants
hospitalized
hundred
focus
Santa
euthanized
graded
carbonate
irrespective
3-fold
MRSA
naltrexone
search
TEAE
enabled
rifabutin
remarkable
Fab
Corp.
hepatocellular
concerning
reactive
Week
kb
employing
V/F
hydrocodone
suffering
consequences
in-vivo
sign
ABCG2
dextromethorphan
MDMA
Instruments
freshly
stream
duodenum
plain
PTA
recognized
percentile
pairs
isoforms
Company
sulphate
Radix
infarction
SPE
undergoes
atrial
concentration‐time
dissolving
G-CSF
donepezil
M4
notable
antipsychotic
angiotensin
therapeutics
gold
historical
Test
hydroxide
inside
108
contributes
siRNA
NVP
mg/L.
Once
categorical
anion
6.9
Waltham
turn
MP
CYP2E1
femoral
Besides
salivary
1999
microbiological
breath
biologically
CDCl3
inadequate
transported
8.4
LPS
Switzerland
micelle
root
PBMCs
genotyping
Neoral
switching
9.2
distal
scenarios
TPGS
CyA
polymerase
MM
PSA
environmental
naloxone
Equation
drops
toxicology
convenient
po
sought
own
myeloid
fluctuations
aerosol
GE
Linear
RP2D
interact
clarify
mL/min/kg
fixed-dose
UGT1A1
lost
haematological
issue
lasted
DAS
vial
indications
GmbH
EGCG
LS
dye
aminoglycoside
phospholipid
approximate
5.9
EMs
7.1
mouth
recommend
pre-treatment
immunosorbent
patches
screen
carvedilol
contributing
unless
inverse
pleural
2018
concurrently
nadir
jejunum
Applied
Dosing
carboxylic
neutropenic
origin
FSH
postpartum
mg/dl
irritation
former
21-day
isotope
excitation
polar
consists
Malvern
excessive
saquinavir
THE
vessel
NO
wound
stimulated
9.0
neurons
remifentanil
no.
ADC
lopinavir
Pharma
k
risks
uric
SNP
scattering
LDL
optical
return
SAD
experimentally
CLR
phenolic
lacking
vincristine
observe
0.19
Primary
seeded
0.24
AUCτ
FBS
detail
PHT
9.5
ear
imipenem
P<0.001
SLN
St
biexponential
host
desirable
persisted
103
PT
proportionally
micro
1998
People
Life
droplet
IU/kg
attenuated
began
parallel-group
Conference
LEV
exert
melphalan
non-small
first-in-human
Roche
ALL
Liquid
exenatide
abundance
subgroups
protected
glucuronides
international
Increased
question
predictable
gels
P<0.01
heat
centrifuge
allergic
repaglinide
captured
Mountain
replication
prevalence
STUDY
proportions
dramatically
μg/L
introduction
indicative
centers
Method
APAP
BBR
antitumour
h−1
glucagon
gland
hypoxia
RI
microg/kg
ABC
polydispersity
apparently
septic
corticosteroids
perfusate
changing
board
lactating
abundant
unable
DL
cages
cytometry
0.21
Quantification
PopPK
8.1
View
adalimumab
fexofenadine
rationale
mesylate
i.d.
crystal
resultant
darunavir
Gy
enalapril
14-day
Low
ophthalmic
cefuroxime
meningitis
cefotaxime
blocks
thrombosis
corneal
adenosine
ones
0.23
monthly
sessions
CYP450
Continuous
Hepatic
nodes
H]+
tea
diverse
NE
dropped
B-cell
suppository
ECOG
stabilization
microm
micrograms/kg
Alzheimer
Upon
cows
referred
interquartile
corresponds
registration
influenza
sulfoxide
steady‐state
attractive
ganciclovir
CPB
0.95
controlled-release
TA
opioids
conscious
ultrafiltration
carrying
created
PPI
single-
8.7
KNOWLEDGE
attempt
remarkably
aid
myeloma
ATV
rational
Michaelis-Menten
moment
DMSO-d6
eg
excluding
FP
ID/g
numerous
min−1
0.32
postnatal
TMP
why
experiencing
lumen
situation
emergence
bioavailabilities
hydration
immunoglobulin
Streptococcus
migraine
budesonide
post-injection
real
fenofibrate
recurrence
Sixteen
PG
37.5
herein
estrogen
9.4
CH
uncomplicated
7.7
apical
inspection
percutaneous
methylprednisolone
CLint
medicines
pellet
identifier
supernatants
DBS
nivolumab
Over
2-compartment
hepatocyte
0.025
performing
S4
anterior
9.3
toxin
infectious
melting
eligibility
D2
termination
interpreted
transcriptase
arsenic
Concomitant
homogenization
pyrazinamide
pioglitazone
Xa
DTG
exhibiting
terminated
Sciex
eliminate
washing
ventilation
Values
chains
fT
nucleoside
13C
striatum
0.26
anti-cancer
albendazole
buffered
Discovery
4B
conditional
HbA1c
glycoprotein
0.98
discharge
O
IFN
0.85
formate
unstable
top
ascites
piperaquine
Regarding
correct
thigh
proton
depend
Between
Novel
ATCC
10.5
display
Caucasians
sarcoma
naringenin
freeze-thaw
Zealand
XR
AUC(0-24
real-time
kill
Recent
700
force
000
insight
prominent
Papp
possess
biochemistry
efforts
newborn
175
modify
side-effects
daidzein
severely
runs
cleavage
AR
0.28
internalization
ambient
forming
extravascular
epithelium
observational
enteric-coated
8.8
IVM
his
Specifically
triglycerides
0.67
designated
EPA
0.27
options
prothrombin
Preliminary
2-
dichloromethane
T3
challenging
segment
triglyceride
12-h
sc
determinant
Eighteen
counting
PP
steroids
2b
non-pregnant
blue
Fifteen
Groups
bortezomib
iii
burst
reasonably
cationic
placental
January
F1
AEDs
EL
107
HSA
toxicological
temozolomide
102
outpatient
101
genotyped
positron
hydrocortisone
pemetrexed
array
mucositis
wells
Formulation
puncture
adjusting
ambulatory
TG
accomplished
BE
aromatic
HP
etc
gum
ANC
monolayer
lean
TT
presumably
prasugrel
mg/m2/day
LNG
inner
CLL
heavily
selumetinib
felodipine
Distribution
Thirty
nonpregnant
Biological
designs
psychiatric
Brain
μg/g
enzyme-linked
adsorption
T1
Department
displays
5A
ischemic
Rb1
dividing
implant
And
insignificant
FTIR
ng·h/mL
3a
Eastern
deionized
mannitol
epidermal
1-2
construct
challenges
DMEM
porcine
axitinib
hydrolyzed
donors
.01
localization
alveolar
hospitalization
atazanavir
afatinib
framework
interfering
L/h/kg
2-week
9.1
venlafaxine
pathology
studying
smooth
residuals
ED50
gram
Association
formal
devices
hemorrhage
intersubject
ON
0.003
8.6
uses
verify
regarded
\left
7.9
psoriasis
ADME
ginsenosides
pore
tachycardia
Age
220
datasets
mm3
salicylate
Free
L/min
heterozygous
I/II
MW
Co
proper
Many
12.0
binary
pazopanib
nucleotide
mitochondrial
BEH
AUC0-infinity
neutrophils
lapatinib
≥1
fu
ingredient
clonidine
osmotic
MCF-7
Events
zolpidem
expanded
0.96
dolutegravir
horse
asymptomatic
foods
operation
protect
monolayers
nelfinavir
chickens
kinases
locomotor
medicinal
colonic
arrest
matching
AUC0-12
Material
Limited
Tumors
encountered
College
pegylated
scientific
Eleven
scenario
isavuconazole
Assay
activator
salts
connected
cannula
temperatures
helpful
NLCs
Dose-limiting
end-stage
acts
hypoglycemia
diets
primates
ethnicity
existed
adapted
developmental
TMZ
0.97
hot
nonspecific
films
physician
pantoprazole
manageable
grown
erythrocyte
nonparametric
sequentially
fetus
pregabalin
attached
percentiles
\times
classical
confirms
GMRs
sucrose
anorexia
Taxol
routinely
Healthcare
correlates
HER2
cartridge
HepG2
teicoplanin
chest
histamine
Stability
antiplatelet
IL-2
Guidelines
equilibration
cyclic
aspart
histopathological
PTH
precipitate
serially
assumptions
considerations
Co-administration
usefulness
propose
Y
320
Ca
RES
complement
copolymer
validity
leukopenia
psi
Science
ACN
inter-assay
Thereafter
duct
AIDS
colitis
amitriptyline
amine
oxidase
bloodstream
substituted
renally
analyzer
Trials
semaglutide
Likewise
cut-off
PEGylation
Vdss
9.6
tools
NSAIDs
Solutions
micellar
uridine
applicability
channels
stated
growing
Cooperative
adrenal
fluctuation
p.i.
CV%
unlabeled
Cur
clamp
implantation
rare
derivatization
lumbar
quetiapine
loop
ascorbic
alprazolam
retrospectively
obtaining
yields
Acquity
4-week
AUC(0-∞
salicylic
trimester
never
MAP
SP
switched
ifosfamide
210
unpublished
4H
conjunction
cm2
herb
Agency
Future
rabeprazole
nimodipine
mammalian
trimethoprim
280
wt
inhaler
UGT
anxiety
T-cell
dilutions
wk
spontaneously
irreversible
soy
PCA
q.d.
clotting
thin
chloroform
PAH
Supporting
modes
0.31
intoxication
abdomen
counted
favourable
poisoning
linker
flurbiprofen
phenotypes
montelukast
metoclopramide
systemically
enoxaparin
0.004
bicarbonate
infiltration
Adult
entirely
1996
clinicians
epirubicin
aluminum
episode
DEX
codeine
killed
I.
vortex
Pgp
retinal
−70
movement
filled
calorimetry
category
AmB
symptom
renin
lethal
cutaneous
plant
least-squares
0.38
knockout
principle
0.30
Molecular
lovastatin
0.92
fumarate
Plus
clean
COX-2
preceding
passed
ROS
noise
closed
100-mg
night
heterogeneity
inulin
controlling
training
rhythm
classes
Conversely
Tac
get
valid
knee
inter-
age-related
octreotide
copper
lateral
12-hour
1997
EPO
pre-
uncontrolled
R-
Gram-negative
passage
liters
creatine
Plasmodium
migration
inversely
transcription
concentrate
Biosystems
California
0.94
antagonism
quantities
acetone
derive
Geometric
Pharmacology
easy
1–2
wet
Tolerability
VI
2,000
precipitated
extend
malignancy
q
scintillation
T4
4-fold
increasingly
Initial
implicated
Various
regulations
River
built
neutralizing
Chronic
A549
integration
0.78
sputum
VPC
DMF
North
Preparation
ip
cut
suppositories
esters
nanocrystals
enables
RR
1-h
Kyoto
intraday
metrics
goodness-of-fit
Vancomycin
freeze
S9
successive
poloxamer
directed
sequencing
records
therapeutically
encouraging
recording
segments
11.5
switch
December
sumatriptan
metabolizer
SBP
transgenic
limb
baclofen
ADAs
bronchial
interruption
follow‐up
Tacrolimus
pertuzumab
Volunteers
avoided
eradication
driven
prespecified
Fourteen
yr
modulate
hormones
yellow
supplemental
\right
wash-out
ezetimibe
electrocardiograms
unacceptable
homogeneous
hippocampus
delta
determinants
Levels
20.0
hourly
cetuximab
0.29
2D
blot
CTCAE
0.36
reverse-phase
columns
IFX
wild
yielding
IgG1
cortical
USP
Diego
NAC
chemically
axis
MDR
regorafenib
enhancer
visualized
primaquine
bioassay
theory
Kp
DBP
suitability
microbiota
post-dosing
covariance
histologically
believed
CFU
simplified
isolate
reader
enteric
anticoagulation
decoction
alternate
single‐dose
Validation
neuromuscular
margin
tazobactam
cornea
enrolment
cysteine
hypoglycemic
replicate
imipramine
digestion
q12h
ixazomib
constipation
White
identifying
diuretic
graphical
A1
facility
Terminology
5th
MIC90
0.39
warrant
signed
checked
16.7
reaches
g/L
glibenclamide
l−1
velocity
RBCs
ultimately
living
ZDV
hazard
tigecycline
manufactured
agreed
exclusively
Rapid
f
hydromorphone
norepinephrine
conditioning
Potential
n=6
0.37
exponent
effluent
So
basolateral
RP
fifth
authorized
RIA
Kit
DP
115
WBC
MI
HPLC-UV
0.93
0.34
Pharmacodynamics
DM
suppress
list
IGF-I
Venous
understood
virtually
CK
differentiation
held
organism
8.9
Female
location
radiotracer
0.66
225
pair
leptin
1st
Period
0.65
swine
submitted
nintedanib
MMAE
duplicate
asked
sexes
citalopram
edoxaban
neuronal
ultrasound
chronically
physiology
ischemia
dependency
−1
opposite
ME
folic
airway
feature
heating
SLE
C6
spiking
N-oxide
0.88
rhein
CH2
mins
mg/kg/d
maraviroc
vector
bulk
toxicokinetics
cigarette
discrepancy
infrared
mucoadhesive
cage
0.42
succinate
nonrenal
triazolam
blocker
carboxylate
3-4
amplitude
motility
docking
spp
Paclitaxel
ondansetron
ABZ
empty
virologic
disintegration
paeoniflorin
glimepiride
Single-dose
PZQ
lorazepam
phosphate-buffered
24h
cream
0.48
equivalents
pivotal
gives
FL
sedative
leakage
retina
Increasing
half-time
recruitment
AUC24
vehicles
CPT
appetite
enter
hepatobiliary
Unlike
piroxicam
canagliflozin
gemfibrozil
radiochemical
congestive
localized
hormonal
5-HT
accuracies
copies/mL
benzodiazepine
degraded
categories
naturally
gradual
author
situations
Charles
ginseng
mL/min/1.73
titers
prove
Synthesis
Europe
roles
implants
shaking
predicts
PDT
reactivity
insertion
Invitrogen
nanosuspensions
possesses
backward
pharmacogenetic
HDL
3–4
faecal
epileptic
network
veterinary
Women
ca
10.8
Hill
macaques
\cdot
spite
drug-free
becomes
SDS
fits
Systems
30-min
June
apoptotic
visible
capability
CYPs
mimic
confirmation
subtherapeutic
fine
0.41
responded
Design
Quality
Simcyp
s.d.
artificial
Rat
L(-1
inform
nucleus
effort
coupling
0.90
pg
inoculation
goat
allopurinol
1.05
135
bioactivity
instance
Candida
generalized
IA
H2O
PBMC
aging
0.44
0.55
John
5-fold
glycine
Eudragit
Recovery
hypothermia
11.1
cephalosporin
marginal
sufentanil
0.84
heavy
toxicokinetic
cirrhotic
electronic
exploration
nebulizer
agar
accounts
market
Average
CTC
revised
respond
collagen
intraindividual
Separation
famotidine
0.91
aprepitant
examining
qd
open‐label
0.89
10.2
0.40
Herein
33.3
diffuse
5-day
h/L
adjust
suboptimal
qualitative
nitric
prolactin
Cp
addressed
0.86
IGF-1
S.D.
F2
Ke
entering
CLcr
Water
chromatography/tandem
Written
log-linear
μmol
MMC
stay
Schedule
resection
Chemicals
absent
But
sertraline
structurally
metal
tofacitinib
mmol/l
AIF
mammary
hyperglycemia
AIC
0.43
-20
CRRT
XRD
naringin
excised
endocytosis
CO
penetrate
g.
0.83
contrary
Absolute
joints
May
112
Metabolic
layers
CUR
M5
Ro
Sodium
dominant
piglets
modulator
PFOA
microscopic
publication
SS
normalization
About
logarithmic
shrinkage
T.
0.63
emodin
Exclusion
1.73
diethyl
sharp
13.5
Previously
hypoxic
sera
kV
Clara
venom
apply
VWF
Products
memantine
lysis
≥2
costs
0.58
alters
Pediatric
bands
NADPH
isomer
electrophoresis
duodenal
ointment
GC
inoculated
vasculature
ICH
flat
contraceptives
nonsteroidal
λz
importantly
naïve
optimizing
plotting
2:1
takes
translation
building
Beagle
Society
uterine
Any
supportive
fiber
trace
0.87
model-based
0.125
definition
g/dL
partitioning
amplification
0.82
floating
HRMS
covered
recommendation
mother
GL
3:1
3C
TC
NaOH
Africa
adhesion
entrapped
staff
DPD
enteral
polypeptide
MRP2
Lack
progressed
mature
PVA
LDH
immunosuppression
AUCt
0.76
numerical
3b
baicalein
EA
persons
minimally
March
thresholds
1.01
emulsions
insights
empagliflozin
rocuronium
Medicines
aPTT
Thirteen
regulated
dose-dependently
forced
occasion
downstream
Ar-H
pomalidomide
0.52
believe
Combination
2D6
1.03
obviously
pre-clinical
micrograms/g
reliably
UC
norfloxacin
guided
cat
questions
v/v/v
cation
elucidated
rosiglitazone
two-sided
illustrate
fragmentation
NK
distance
exerted
1.02
administer
postinjection
odds
somnolence
0.47
200-mg
atmosphere
oncology
existence
TCDD
2–3
OD
10.3
MCR
brains
autoimmune
ultra-performance
ketorolac
albino
grades
intrathecal
Inclusion
fluvastatin
involve
polypropylene
15.0
±15
placenta
notably
plaque
Milli-Q
nutritional
outlined
Concentration
enantioselective
Whole
r(2
link
Bu
daunorubicin
pentobarbital
Repeated
MPAG
stretching
angle
FTC
utilization
hemophilia
Sweden
July
0.72
ceftiofur
influx
mothers
band
g/day
parametric
attain
IVR
prostaglandin
s.
95th
K.
Whereas
October
chimeric
1C
U/kg
0.81
appropriately
home
NHL
erythropoietin
detecting
5B
dioxide
illustrates
Eppendorf
time-concentration
topically
drip
50:50
0.56
scales
0.77
reversal
g/m2
offered
scaffold
express
l-1
quantitated
SB
lopinavir/ritonavir
ice-cold
unmodified
dapagliflozin
CrCL
recirculation
durations
Thai
AUC0-inf
unlike
Descriptive
1.75
sigmoid
clindamycin
CQ
flavonoid
Italy
0.54
anti-Xa
racemate
CM
cephalexin
threefold
10.6
0.49
0.53
propylene
V.
188
9.9
isolation
Apparent
anhydrous
April
hydroxyl
lecithin
9.8
Materials
/
World
0.73
C(18
11.0
systematically
statins
collect
ultrafiltrate
Modeling
etravirine
Pearson
squamous
endocrine
ACTH
reuptake
time-course
HCT
aortic
flask
streptomycin
delivering
node
sealed
pefloxacin
levonorgestrel
chloramphenicol
stomatitis
DCA
Seoul
bag
nitrate
rich
Enhanced
IC(50
secreted
cardiotoxicity
Nanjing
Experiments
AUC(0-12
pruritus
kilogram
thawed
HBV
non
telmisartan
10.4
0.64
spread
million
AF
longitudinal
NET
Activity
1.04
September
S-warfarin
BM
S5
HBSS
2-3
univariate
1,200
Biodistribution
supine
128
adducts
Randomized
LLC
depth
inactivation
Drugs
discontinuations
marbofloxacin
remainder
eluent
exclude
liraglutide
orange
1–3
1H-NMR
amenamevir
1-week
morbidity
longest
difficulty
q8h
perhaps
glioblastoma
catheters
bosentan
0.46
cytarabine
correspond
Morphine
direction
static
ulcer
Guide
woman
discovered
guideline
dimethyl
Current
sonication
priori
0.68
three-way
differing
slow-release
BAL
Ethical
freely
maximize
attempted
Currently
PN
lenalidomide
weighting
0.74
titer
reservoir
florfenicol
Biosciences
drink
her
allograft
intercompartmental
sensory
SAR
doubled
Rg1
transfected
biosimilar
hydrochlorothiazide
dextran
heterogeneous
Heart
aldosterone
olaparib
instability
decided
11.3
split
Subsequent
matter
syrup
SPECT
two-fold
CE
10.7
sinus
LPV
50.0
solubilization
reliability
haemoglobin
C57BL/6
promise
chose
additionally
Compounds
preserved
UGT2B7
elective
Certara
freeze-dried
BIS
counter
0.62
shortened
proteinuria
ionic
bw
micafungin
profound
0.57
radical
HSCT
tiotropium
noninvasive
psychomotor
inherent
piperine
Biotechnology
Excel
p<0.001
Unit
PARP
keeping
LDL-C
DON
TRAIL
12,000
fluticasone
persistence
modelled
glycerol
macrophage
colchicine
Zorbax
LV
robustness
paw
reproductive
morphological
pathogen
orthotopic
2–4
PCSK9
TNF
engineered
prognosis
taste
questionnaire
East
contributions
eV
0.61
U.S.
probable
equimolar
virological
microliters
VIII
phenacetin
moieties
rapamycin
elsewhere
CVVH
0.71
Figs.
compatible
antacid
MBC
mL-1
CTX
11.4
lavage
implementation
titrated
TCA
adaptive
intratumoral
hydroxylated
plastic
meta-analysis
preferentially
compatibility
slices
clobazam
oxidized
25.0
COMT
anti-human
desipramine
R1
270
18.5
categorized
chromatogram
Assuming
fibrillation
TS
stimulating
RH
Correlation
Crohn
TBW
popPK
varies
delays
flunixin
aflibercept
establishing
corticosteroid
hGH
increments
Precision
antiarrhythmic
carbohydrate
putative
Aldrich
aminophylline
TD
ineffective
3,000
BCS
0.79
surrounding
micrograms/mL
TX
paliperidone
11.2
leukocytes
n=3
broad-spectrum
C3
novo
3-week
Monitoring
Key
iohexol
Microsoft
intercept
solely
Dox
multicentre
oven
CHF
scored
thoracic
colloidal
11.8
spectrophotometer
Rd
crystals
electrochemical
Chromatography
timepoints
I.S.
possessed
repair
contraception
bilayer
NA
mitomycin
catalytic
diameters
9.7
Accuracy
Q2W
transfusion
5FU
discomfort
RD
Radioactivity
read
facilitated
progressively
obstructive
centre
cardiopulmonary
fatal
disruption
monocytes
actually
warrants
outer
Kinetic
1995
indeed
mTOR
plausible
emerged
P‐gp
W
eventually
MeOH
antidepressants
isoflavones
Early
IVIVC
glutamate
soybean
ultra
Complete
drainage
SDs
antineoplastic
excipient
Prospective
consistency
Vd/F
HC
Spearman
neuropathic
module
VT
Chicago
undergone
carotid
Stage
elicited
SN38
OCT1
leucovorin
Darmstadt
resuspended
signalling
170
atypical
relating
homeostasis
altering
Kel
fosfomycin
cartridges
between-subject
KD
blister
thromboplastin
formulae
aglycone
calibrated
10.1
careful
Central
EPI
leukocyte
ROI
0.51
Pfizer
oligonucleotide
blind
chow
worldwide
CD8
_
vortioxetine
deuterated
comparator
eribulin
synthase
IRB
Demographic
called
RCC
format
acetylation
augmented
presenting
pH.
micronized
cm/s
usage
members
ITT
spatial
0.006
PPD
intense
gliclazide
fluoroquinolone
ATP
maximum-tolerated
put
tobacco
procainamide
GM
weight-based
pyronaridine
LD50
LC/MS
4C
SI
phosphoric
newborns
VA
ITZ
competition
CYP3A5*3
phenyl
filtrate
insomnia
healing
biodegradable
androgen
acetylators
learning
covalent
he
first‐order
repeatedly
bonds
Unfortunately
incubations
EP
niosomes
C8
fluorescein
trauma
topiramate
0.999
enabling
L-dopa
relate
PI3
hard
mg/g
selenium
null
code
SAE
230
phenotyping
captopril
post-administration
premedication
11.9
pharmacokinetically
2-h
Characterization
Rhizoma
DPI
nmol/l
menstrual
physicians
antisense
coverage
aminoglycosides
13.2
embedded
neuroprotective
DPP-4
EU
ethambutol
whilst
egg
freedom
releasing
allogeneic
lenvatinib
X1
opportunity
simulating
atropine
broth
sevoflurane
extracorporeal
glucocorticoid
t.i.d.
Australia
methylation
VL
antinociceptive
TFV-DP
summarizes
thoroughly
HQC
cerebellum
14.3
intraocular
worsening
haplotype
Re
123
latency
Prediction
deletion
3-
August
GB
0.60
intravascular
alopecia
RSV
methylphenidate
P-450
digestive
AChE
widespread
stratum
November
preference
deposited
Trough
X2
single-blind
Comparing
TPM
definitive
gentle
17.5
ADCs
translate
AKI
Injection
0.69
coffee
light/dark
3-day
primate
mood
CMV
avoiding
Those
Analytical
manufacturing
N2
10-mg
postdosing
Cl/F
powerful
starch
phospholipids
T2
inoculum
Maximal
111
nitrite
thaw
0.008
perampanel
adolescent
DS
neuroblastoma
positions
amounted
MDA
113
lining
structure-activity
signal-to-noise
maximally
non-specific
highlight
colony
Institutes
recognition
feedback
subsets
cetirizine
ferulic
inversion
exerts
caspofungin
burn
interspecies
Aliquots
High-performance
unpaired
PrEP
ADHD
thiopental
indicators
vitro-in
anaemia
permit
AUC0–12
11.7
M8
pumps
fluoroquinolones
hemolysis
DLS
quantifying
10.9
2500
Analyses
LQC
microbial
Intra-
12.8
CMC
lymphoblastic
programs
STS
IT
CVVHDF
wash
resting
AAG
cotinine
digital
0.70
confocal
test/reference
advantageous
resin
personal
enzalutamide
nilotinib
12.4
polymorphic
FIX
hydrogels
TFA
Parameters
create
C1
Indian
parasitaemia
unaltered
RSE
i.n.
Pluronic
focal
drug-induced
0.59
MDA-MB-231
atomic
TTP
resorption
library
Daily
placement
Recombinant
126
1.06
TLC
dasatinib
weakly
letrozole
long-lasting
Harmonisation
domains
PLD
strengths
mixed-effect
90%CI
implying
implies
μL.
diluting
intestines
Pretreatment
fairly
microgram
catabolism
distinguish
l(-1
OTC
running
p53
complexation
folds
kinds
-80
linkage
MAb
well-known
13.3
15.5
cilostazol
BSV
1.08
B1
thalidomide
emtricitabine
mitoxantrone
Diagnostics
Metabolite
Child-Pugh
MF
color
plexus
life-threatening
achievement
1:2
12.3
HIV-1-infected
Volume
prevents
bottom
Together
progress
cassette
1-
C(min
member
minimizing
febuxostat
ΔOFV
appreciable
imaged
1.12
VCR
5-ASA
Vz/F
emerging
1-3
maleate
sponsor
attenuation
acyl
\
smallest
e
contrast-enhanced
increment
bedaquiline
compression
dose-adjusted
lysine
pituitary
Imaging
indocyanine
mutants
Impact
amantadine
CYP2A6
glycosides
S6
Reference
exon
NSAID
polyphenols
116
AI
chlorzoxazone
morbidly
thorough
6A
375
muscles
benzodiazepines
comparatively
11.6
ECF
microsphere
cluster
Acetonitrile
PL
MT
stavudine
antidiabetic
Act
compromised
Insulin
radiolabelled
promoting
12.7
equine
Visual
pathogenesis
enrichment
roughly
completing
stabilizer
Estimated
insoluble
variabilities
granulocyte
12.2
preferential
promoter
arithmetic
arginine
vivax
SEDDS
simply
EE%
engagement
CAPD
Objective
day−1
EtOH
cannulated
TO
1.13
complexity
globulin
transform
0.015
task
Lower
HEPES
York
indwelling
Appendix
filters
lispro
B2
LDX
Inhibitor
drug-metabolizing
CoQ10
cough
cannabis
Extraction
granisetron
pKa
zone
checks
neurologic
characterised
IU/mL
histology
influenzae
plasmid
institution
1600
peritonitis
SIM
confounding
differs
alcoholic
stool
contamination
IIA
converting
roflumilast
fructose
numerically
nanoemulsions
presystemic
affinities
rinsed
glands
isoform
presumed
Nonetheless
ke
soon
cDNA
corn
assume
inferior
400-mg
22.5
adduct
PPIs
-1
peginterferon
GABA
restriction
reconstitution
silymarin
Arm
That
inability
veins
dairy
HF
Gram-positive
histone
lipoproteins
RP-HPLC
droplets
Regulatory
cooled
GEM
meeting
radioligand
pill
Excretion
redistribution
afforded
managed
12.6
non-small-cell
Princeton
nonhuman
NCA
prescribing
formoterol
tracers
milliseconds
natriuretic
4a
posttreatment
injecting
50-mg
herbs
spectral
high-risk
twelve
necessarily
AUCss
TQ
METH
public
dose-finding
overlap
ABCC2
polyclonal
colleagues
pre-treated
6000
vesicle
birds
stopping
unity
1100
achieves
iodide
TMDD
K1
adjunctive
12.1
manual
420
coded
non-parametric
shortly
Council
characterizing
aggregates
sigmoidal
IC
noticed
erythema
hydrodynamic
Generally
QRS
oxytocin
dehydration
Section
interventions
Collectively
Online
grid
Factor
Swiss
encoding
selegiline
Nonlinear
ODT
TAM
recycling
260
D.
1,500
confined
CML
depressed
topoisomerase
nonsmokers
silver
angina
General
Ct
efficacies
dramatic
cover
emergency
qualified
Index
ethinyl
sulfone
foals
lipase
breakpoint
western
carry
non-Hodgkin
brand
Li
receiver
TCI
Initially
15.6
Cyclosporine
D1
13.0
abacavir
summarised
insert
Dogs
MAC
elements
immunohistochemistry
prognostic
Organization
congenital
C/D
colony-stimulating
Physiologically
supply
genetically
am
Combined
circulatory
Evidence
collections
default
tau
complementary
LMWH
surfaces
intensities
incidences
1.15
viruses
RMP
abnormality
proof
mexiletine
ascorbate
Services
modulating
transaminases
14.5
slopes
survived
tight
Improved
DE
121
254
95%CI
μM.
project
ALP
BU
aorta
lactose
CMS
BUN
fibrinogen
©
Binding
PET/CT
drug-loaded
mol/L
depressive
Across
national
sec
didanosine
2nd
arrhythmias
Centre
minus
luminal
GC-MS
IBM
camptothecin
Whether
haemodynamic
ATO
doubling
Reagent
paradigm
CHO
calcitriol
difficulties
conducting
whereby
F3
≥50
1.5-fold
aggressive
AUC0–inf
electrical
record
ara-C
displacement
albicans
filgrastim
1.07
approximation
deficits
supratherapeutic
Harmonization
enriched
proteasome
Therapy
abiraterone
deficient
N-desmethyl
highlights
gained
osteoporosis
worse
metabolised
UHPLC-MS/MS
ABP
190
DCM
rebound
ciclosporin
sugar
beverages
prototype
compensated
v.
blockers
menthol
aptamer
mmol/kg
small-molecule
opposed
Noncompartmental
MDS
phosphorylated
misoprostol
February
vortexing
transferase
extreme
tulathromycin
State
SGLT2
TM
sonicated
adaptation
dorsal
sitagliptin
missed
0.083
kind
bilateral
compositions
216
diurnal
neonate
tertiary
Interaction
methamphetamine
unexplained
incision
HP-β-CD
2-period
VCM
IgM
intracranial
inorganic
117
IX
SV
originally
gallbladder
intra-individual
camera
triptolide
13.6
computational
Pharmacological
Vital
relaxation
ST
Measurement
uninfected
glycemic
autoradiography
BCA
Pain
responsiveness
panels
endotoxin
Professional
hind
multidrug-resistant
alkaloid
hold
specimen
p<0.01
b.w.
GBM
Å
T-DM1
1.10
PF
veliparib
114
CZP
CD-1
ICR
discharged
trained
albeit
discretion
autologous
evacetrapib
isoflavone
transplanted
quick
MC
HLB
Intestinal
intrasubject
MPS
Tianjin
interim
till
talinolol
Rating
polarization
145
OH
spot
deterioration
SAM
prostatic
dapsone
nanocarriers
CRC
curative
Third
nM.
laboratories
1.09
720
superiority
Table1
kits
14.4
Optimization
asthmatic
1994
phosphatidylcholine
ewes
Global
2-4
anaesthetized
EPR
HT
draw
cyanide
selecting
protonated
rated
100-fold
duloxetine
heroin
sham
slides
once-weekly
amphetamine
analgesics
amniotic
extra
subpopulations
aspect
n=5
12.9
Forty
Bonferroni
incubator
13.1
hamster
minocycline
Theophylline
tear
constituent
highlighted
OUR
subtypes
logarithm
cisapride
choline
document
ATRA
Kinetics
MN
guard
medians
noteworthy
16.0
Thailand
manually
verinurad
potentials
1–4
CURRENT
timolol
Dissolution
dermatitis
Vz
reveals
precisely
statin
transiently
exposure-response
inflamed
incremental
geniposide
sulbactam
live
emulsification
benign
6B
scintigraphy
CH3
worth
192
CHANGE
Mann-Whitney
anatomical
approximated
1.14
adjacent
terbutaline
non-steroidal
anti-TB
MIGHT
Akaike
incorporate
played
13.4
neural
propafenone
C4
isozymes
gliomas
weaker
modulated
removing
scFv
methicillin-resistant
beta-lactam
recordings
perspective
d.
TSH
2C9
degeneration
tubule
potently
powders
exceeds
13.8
dissolve
15.4
demethylation
gently
BG
0.007
modulators
inconsistent
solute
follicular
nitroglycerin
He
initiating
KO
AUCtau
RO
1-hour
continuing
instructed
propionate
methylcellulose
VTE
Resource
62.5
plasminogen
omadacycline
span
preceded
schemes
4-h
rating
intubation
Class
nortriptyline
Bayer
secretions
anionic
postulated
secretory
Subcutaneous
aforementioned
EMA
Bruker
width
nomogram
pylori
translational
predictability
striatal
2.00
peroxidase
depended
mechanism-based
thrice
a.m.
subunit
glargine
PFOS
anthracycline
1.17
ROC
NAT2
lactation
IL-10
tedizolid
umbilical
acidified
methylene
iodine
SRM
Belgium
Se
chromatography/mass
endometrial
buspirone
LF
Windows
figures
lycopene
GCV
VII
5,000
regularly
convenience
sclerosis
high-throughput
6.25
obstruction
allergy
linagliptin
mg.kg-1
milliliter
HCQ
2.25
IBU
haplotypes
hyperplasia
Dr.
Mycobacterium
carbidopa
gram-negative
halothane
Small
IL-1β
time-points
Midazolam
U/mL
versa
pmol
•
13.9
failures
prohibited
diuresis
Taking
potencies
Performance
1.50
azathioprine
exudate
mL/h
CLZ
underestimated
endothermic
C-peptide
pressures
BC
preparing
99mTc
enhancers
occlusion
Immediately
nested
tadalafil
barriers
650
haemophilia
Where
A2
intra-assay
shaken
UDCA
suffered
Particle
hydrate
activate
match
G1
tolvaptan
ethylene
Ciprofloxacin
NLC
TR
individualization
kel
nonclinical
eq.
monoamine
liters/h
stimulus
300-mg
Novartis
Long-term
centres
fulvestrant
1.11
afford
West
in-house
cefoperazone
discrimination
alemtuzumab
mg/mL.
ith
SF
solubilized
backbone
Steady
CG
designing
marginally
emesis
p-value
goodness
Clinically
childhood
LPV/r
µg/kg
Tukey
anesthetics
vehicle-treated
bpm
lymphocytic
beta-carotene
inter-patient
ramipril
GHB
calcd
127
[M+H]+
suggestive
honokiol
stationary
SOD
ISF
AGP
Arterial
acutely
ADR
ejection
flexible
Zetasizer
intolerance
triphosphate
closer
Metabolites
PGE2
three-period
diagram
Fourier
Severe
C24
steric
immunotherapy
pharmacy
ATZ
researchers
silybin
16.5
visually
Cmax⁡
assessable
3-h
breastfeeding
brands
Comparisons
mineral
approached
slowed
3rd
agitation
reticuloendothelial
hypothetical
14.1
Methanol
temsirolimus
vice
TOPIC
clot
stimulate
compares
subtype
Higuchi
frame
HOW
inferred
G2
preoperative
adriamycin
alginate
407
6H
leukaemia
translocation
RPMI
GR
phenotypic
keep
plated
smoke
rarely
cephalosporins
Independent
netilmicin
challenged
trazodone
ovary
publications
hysteresis
defining
LP
pyrimethamine
leukemic
impacted
electrolyte
desolvation
gatifloxacin
microplate
Statistics
tetracycline
benzene
integrin
hospitals
reflex
extrusion
C-reactive
Simulation
rilpivirine
HLM
MSNs
SM
glycyrrhizin
HS
500-mg
Genetic
H3
liters/kg
LSM
disodium
cone
disturbances
sotalol
antiproliferative
spacer
mTHPC
ease
Zn
effusion
Orally
18.2
plan
Linearity
≥10
bioanalysis
copolymers
QCs
automatic
Estimates
interferences
Park
GG
CSA
concentration-effect
Though
Seventeen
phenylbutazone
Full
bipolar
mg/h
radionuclide
shifts
upregulation
Fischer
ipilimumab
hydroxy
innovator
synergy
anaesthetic
excreta
exhaled
SIF
unresectable
14.0
crossed
Dynamic
Mouse
OATP
recover
amphiphilic
two-tailed
NH
non-invasive
Foster
MCT
reflux
118
6-month
dextrose
2C19
upadacitinib
restored
AUC0–24h
lambs
Less
carfilzomib
glyburide
Mumbai
NCI
Union
antiemetic
Vivo
hydrochloric
UGT1A9
LE
genomic
paraffin
descriptors
ESL
explains
fourfold
Pharmacy
DF
ligation
TCM
probabilities
tubules
1-compartment
ammonia
diseased
comorbidities
sulfation
parasitemia
DID
1.24
Through
drug-resistant
anti-malarial
metabolically
covalently
presentation
17.0
Wang
rising
phenomena
Cambridge
uniformly
cigarettes
5a
formalin
Except
stop
chance
AED
microg/g
cleaved
updated
within-subject
candidiasis
attributes
UMEC
1.23
overexpression
Specific
Curcumin
SGF
nasogastric
Nineteen
motesanib
cells/well
1.33
Simulated
nuclei
clone
NAPA
dose‐dependent
disoproxil
etexilate
SQV
hyperthermia
juvenile
placebo-treated
preferable
second-line
terbinafine
algorithms
declining
retain
ertapenem
disopyramide
candesartan
EC-MPS
electrostatic
adhesive
N-terminal
poly(ethylene
SDS-PAGE
Activities
examples
belinostat
TE
γ
shifted
IPA
Fluorescence
ml/min/1.73
ghrelin
prolonging
Dose-dependent
overlapping
550
transl
Positive
flows
responding
circuit
Toronto
Cohorts
lot
film-coated
tegafur
exacerbation
nanomolar
Klebsiella
Dulbecco
sometimes
WI
Measurements
m-2
plasmatic
13,000
collecting
expect
14.8
micromol/L
Taiwan
HI
breathing
recipient
inter-subject
Weight
Identification
Collection
QUESTION
Cu
covering
one-third
1:3
xanthine
repetitive
Lung
mercury
1.16
outliers
grouped
estrone
14.7
dexlansoprazole
Sensitivity
CAB
119
between-day
anti-tumour
CAP
Table2
Ib
histopathology
effector
FK506
OCT2
1993
activating
14.6
qualitatively
109/L
bacteriological
antipsychotics
0.0
PCB
flexibility
sexual
consuming
graph
dissected
permeable
expectancy
scanned
LLE
manifested
immunological
crizotinib
Target
ADDRESS
lysates
pyrexia
intrapatient
wort
ADRs
FT-IR
ulcerative
beverage
NT
relapsed/refractory
luciferase
NF-κB
FBZ
terfenadine
calcitonin
IHC
Predicted
.0001
Kd
crystallinity
336
Conclusion
FT
identity
immunosuppressant
oxazepam
discarded
social
3–5
diphenhydramine
2-hour
122
erosion
KM
25(OH)D
pitavastatin
discrete
somatostatin
tartrate
wider
enalaprilat
accordingly
Stable
formulas
fruit
cannabidiol
ddI
packed
T(1/2
APTT
dopaminergic
achievable
mol
build
PerkinElmer
nocturnal
acetylsalicylic
microg/L
≥18
ICON
Academy
TID
idiopathic
Kingdom
explaining
ponatinib
10−6
pathogenic
driving
nutrition
modestly
allocation
tend
t-PA
Hypersil
peroral
absorptive
moxidectin
Cox
tolterodine
rucaparib
radiolabeling
FU
interacting
pH-dependent
Torrance
microcapsules
praziquantel
thromboxane
fludarabine
15.2
ACR20
myocardium
L/hr
imply
stasis
saponins
survey
carcinomas
LSD
powered
20-mg
Observed
cubic
copy
xenobiotic
practically
behind
ways
scoring
Billerica
TBI
translated
porous
assist
5-HT1A
centrally
squared
t1/2β
ventilated
GIST
deconvolution
amprenavir
Dosage
oxcarbazepine
n=1
Gd
olmesartan
Delivery
glucuronidated
intratracheal
rules
technical
prematurely
C3435
impacts
mix
Details
pyridine
parental
two-
kaempferol
pelvic
graphically
66.7
minimized
falling
biopharmaceutical
Docetaxel
high-affinity
calf
shell
16.1
diversity
Stock
allelic
ACQUITY
mumol
hypnotic
Spain
Metformin
NF
0-24
rutin
disseminated
endoxifen
chromatography-electrospray
UGE
citric
hip
elicit
articles
demonstration
contralateral
lens
visualization
actively
desmopressin
personalized
mg/kg/h
haematology
volatile
postinfusion
1.35
Gastrointestinal
Conclusions
Selective
conditioned
Direct
standing
vorinostat
belimumab
CES1
clavulanic
S/N
promoted
DXR
M7
perioperative
indirectly
15.8
SCH
BLQ
5-
6–8
mediate
timed
arteries
nursing
hr-1
milling
Abbott
lymphoid
person
Rifampicin
quaternary
17.6
catalyzed
monomer
LSS
124
speculated
multiple‐dose
OAT3
Eclipse
LVEF
hERG
Vitamin
esterase
30.0
fimasartan
athymic
orders
intraduodenal
HDAC
glycoside
ibrutinib
mL.
arrhythmia
assignment
anidulafungin
meglumine
averaging
fetuses
AQ
bradycardia
opening
idarucizumab
Interindividual
community
doxorubicinol
Release
chlorpromazine
Statistically
tryptophan
ertugliflozin
NOAEL
bendamustine
ISO
Terminal
clonazepam
Bioanalytical
decisions
durable
Enterobacteriaceae
loratadine
Models
personnel
\end{document
gift
PXR
double‐blind
dispersible
Advanced
carnitine
venovenous
instances
primers
CD20
homogenous
loperamide
sinusoidal
AUC0‐∞
cured
invasion
receptor-mediated
antiangiogenic
Peripheral
2019
ethinylestradiol
CPA
3TC
leaving
Differential
modifying
ACT
sequestration
spironolactone
Kidney
flecainide
fibrin
QW
post-hoc
diagnostics
Investigation
P>0.05
bed
polysorbate
ALK
Taxotere
refined
site-specific
AMP
132
Mild
enoxacin
2.5-fold
industry
strongest
MG
Nano
256
Pulmonary
metabolize
humidified
low-fat
dipyridamole
avibactam
amoxycillin
Creatinine
ascertain
Variability
muscular
Cr
AR-C124910XX
PLA
10(6
generating
suited
apremilast
GP
hypotensive
Receptor
cefiderocol
0.016
AUC0−t
22.2
18.0
Twenty-one
Local
AMI
physiologically-based
regulating
template
palmitate
vandetanib
1.21
4b
muscarinic
18.8
subpopulation
tert-butyl
determines
Large
two-stage
1.56
phosphorus
N-demethylation
GT
CCl4
DTPA
Vp
electrocardiographic
second-generation
non-Japanese
cAMP
penetrated
rFVIIa
GVHD
round
80–125
spots
Tris
mCi
temporary
NR
inclusive
i.g
normotensive
cosurfactant
conformation
Typical
golimumab
Aβ42
post-transplant
Bcl-2
Accumulation
amodiaquine
PC-3
4:1
quadratic
nicardipine
comedication
IOP
Increases
TCE
Infusion
palbociclib
oleic
DOCX
λ
diphosphate
Scheme
multocida
Significantly
IOV
self-administration
4–6
adsorbed
xenobiotics
Cavg
benzoic
bumetanide
antithrombotic
Quantitation
CYP3A4/5
uracil
self-emulsifying
q2w
AKT
MEM
16.4
FOLFIRI
13.7
prevalent
µg/mL.
6-
4th
team
ratings
PZA
4-
exploring
±20
causal
tanshinone
Zhang
model-predicted
sCT
lunch
ROIs
differentiated
Major
mg/m(2)/day
perilymph
awake
tension
3.84
apigenin
14.2
coarse
asthenia
dutasteride
visceral
ALA
intraoperative
DEHP
lambda
correctly
breakthrough
lutein
request
flora
Residual
extrahepatic
non-significant
Eagle
thymus
15,000
whole-blood
NIR
1.26
os
215
borneol
bisoprolol
4,000
H2
br
weight-adjusted
blotting
oligonucleotides
MPC
model-independent
vortex-mixed
fused
genital
establishment
target-mediated
promotes
G3
chlorogenic
OATP1B3
CRF
Austria
cefquinome
1.67
amyloid
vinblastine
Span
SRL
Caffeine
add
etanercept
Analyst
HER2-positive
rFVIIIFc
scatter
nebulization
responsive
C12
toluene
anastrozole
Half-life
quartiles
Pro
Fifty
closure
Ex
fluorouracil
1.22
Again
alkylating
Whitney
sink
Culture
approx
paralleled
thromboembolic
1.20
Propofol
ruled
complication
expiratory
acidosis
glucosamine
X3
isoenzymes
throughput
intranasally
outpatients
cabotegravir
broilers
estimations
Formulations
population-based
BIA
micromol
1992
antigens
Physical
vecuronium
ascribed
domperidone
similarities
transferrin
attachment
reperfusion
Non-compartmental
necropsy
TK
Haemophilus
pairwise
Cytochrome
timepoint
HCPT
scutellarin
quizartinib
UHPLC
suppressing
Product
autoinjector
IACUC
30-minute
6-h
one-step
hypotheses
136
accelerate
R.
hexane
monoexponential
PSC
ISIS
valve
aldehyde
olive
EtOAc
0.012
ultrasonic
uncertain
U/L
1.43
representation
advance
mg/m2/d
cartilage
necrotic
behavioural
Na+
rotary
vaccine
Michaelis
Asians
Dictionary
America
1.38
1.28
periodically
1.27
amendments
Bio-Rad
rifapentine
box
C-terminal
BCNU
τ
functionality
concentration-versus-time
theoretically
corneum
bridging
chambers
trifluoroacetic
8-h
fulfilled
CVs
oxygenation
hamsters
E1
Addition
La
1.18
sucralfate
cabazitaxel
injector
esophageal
satisfied
offset
Covariates
0.009
hemorrhagic
inpatient
Flow
stably
she
mounted
efficiencies
Perkin
99.9
NIH
PH
Estimation
defects
3.75
70:30
Subject
classic
Fe
constructs
HL
informative
1A2
ventricle
jejunal
Parameter
FLT3
triethylamine
Acid
maps
non-renal
F4
Factors
danofloxacin
artemether-lumefantrine
tried
luseogliflozin
Ca2
mild-to-moderate
low-density
licensed
taurine
aztreonam
breakpoints
Final
131
ARV
protein-bound
microsome
hardness
escitalopram
herpes
Elmer
1.44
chrysophanol
world
RMSE
3500
thiol
Background
hemofiltration
phenol
exit
glucose-lowering
ionized
levothyroxine
superoxide
Gentamicin
macrolide
undesirable
caffeic
stimuli
single-arm
disulfide
taxane
eosinophil
ferrous
on-line
PMA
hematoxylin
allosteric
Working
regulate
4-6
electrode
conservative
OF
poly
Luna
cholinesterase
treatment‐emergent
adequacy
imprecision
leuprolide
apomorphine
1/x2
ternary
acetylcholinesterase
Y1
caudal
doripenem
MQC
mucus
copies/ml
pores
coumarin
syndromes
solubilizing
gram-positive
sulfamethoxazole
WA
ulcers
differentiate
detoxification
testes
microL
lignocaine
Gd-DTPA
avoidance
gross
compensate
NaHCO3
NMDA
AUC0−∞
justified
1.32
regards
ACR
attempts
chromium
time-point
compromise
14.9
165
u
consensus
lysosomal
chicken
smoked
Protocol
microemulsions
spent
gastrectomy
tricyclic
know
Transcutol
ISDN
ticlopidine
atmospheric
Matrix
responder
atom
Note
M-1
moving
tolerate
Normal
totally
once‐daily
13C-NMR
nonlinearity
boosted
tap
regeneration
eosin
biocompatibility
possessing
noticeable
instilled
radiopharmaceutical
reporter
tubing
Jose
integral
anxiolytic
Optimal
projected
unusual
Corresponding
differently
DC
goals
133
downregulation
24.0
DCE
substudy
15.1
Doxorubicin
testis
L-1
paddle
SDZ
mental
isosorbide
miltefosine
dendrimer
uremic
orbital
F.
ARS
safer
Faculty
primer
nanomicelles
accessible
saxagliptin
share
SUV
parents
20-fold
mL/h/kg
surgically
BV
15.3
capillaries
flash
carryover
nontoxic
nitrendipine
qPCR
Hitachi
oxytetracycline
1D
immobilized
daytime
fivefold
radiolabel
equilibrated
Prolonged
Denmark
1-4
inserts
OT
retard
triamcinolone
Alternatively
aglycones
Mn
swallowed
χ2
trap
hydroxypropyl
nicotinic
HGF
ATA
single-centre
Active
broadly
dwell
PDF
strict
ADP
machine
trypsin
breakdown
equipment
analogous
137
stromal
shortening
neutralization
mifepristone
Little
sac
±SD
UFT
Beckman
Q3
Cumulative
sixth
osteosarcoma
olfactory
Uptake
factorial
cyclodextrin
ESM
Biliary
non-human
5C
Treatments
homozygotes
toxins
histologic
biosynthesis
Y2
ODS
substituent
CBDCA
wine
FITC
autoinduction
1.45
entacapone
surprising
VP
q3w
AUC0–last
formulate
properly
uncoated
strictly
clomipramine
chelator
anticoagulants
centrifuging
acceptability
multiplied
arising
15.9
leg
scopolamine
stochastic
Biotech
uterus
evolution
Corning
H-phenyl
H4
L−1
ESI-MS
16.8
quantitate
0.013
Siemens
vasopressin
shaker
kindly
lactic
supersaturation
graphs
dinitrate
epoetin
brought
yeast
anaerobic
indexes
RTX
PRO
swallowing
naive
Mrp2
≥90
auto-sampler
nanocapsules
Twenty-five
Penetration
glyceryl
valganciclovir
ranibizumab
0.017
microdose
beagles
intra-subject
AUC0-24h
Child
milligrams
degasser
off-target
16.6
freezing
nonresponders
hydrolase
false
one-sided
HMG-CoA
herb-drug
oxymorphone
verification
densities
riociguat
stabilize
Antibody
nebivolol
Cmax/MIC
Reduced
CD101
frontal
non-hematologic
HES
dead
radius
MDCK
alkyl
biased
cefoxitin
sofosbuvir
broiler
atoms
BNP7787
paeonol
wavelengths
ataxia
−2
opiate
dFdU
Possible
134
named
variances
implied
Mobile
RG
expired
ACV
nephrotic
Intensive
IDV
VP-16
J.
service
niosomal
pediatrics
interassay
enterocytes
paracellular
17.7
eliminating
overestimated
potentiation
retinol
ED
causative
R(2
hydrophobicity
leaves
nonrandomized
1991
shear
facilitates
fleroxacin
IAsp
ACS
RPV
17.8
Asia
transporting
endothelium
microl
forearm
Classification
ng.h/ml
parameterized
Glucose
calcineurin
fractionated
declines
CD3OD
discussion
20.8
rhGH
4-hour
Mann
sequelae
1.30
commenced
intra-arterial
cytosol
radiographic
10-
irradiated
l/min
immunomodulatory
≥4
GnRH
age-dependent
attaining
meaning
transparent
Nanoparticles
counterparts
potentiated
lysed
day-1
IBD
quinolone
1.34
cell-based
internalized
electrocardiography
ng.ml-1
mesna
Efavirenz
mg·kg−1
β-lactam
extending
analyse
rings
Owing
23.5
330
Bedford
15.7
Traditional
Relationship
Standards
acetylcholine
atomoxetine
PRA
kg/m(2
salmeterol
wave
distress
Cav
1.65
tubulin
CD34
lupus
planning
briefly
seventh
authentic
SCD
344
glipizide
born
lisinopril
ferritin
RBV
dedicated
vedotin
accumulates
lots
permanent
immature
162
facilitating
FLU
prone
tocilizumab
anthocyanins
scanner
displaying
ASO
enters
O2
Chengdu
dyspnea
galactose
alisertib
masses
ototoxicity
portions
lysate
bioadhesive
SCID
homogeneity
Detailed
≤2
opinion
pills
sparfloxacin
Firstly
1–5
80-125
decades
polymerization
THP
Twenty-six
Optimized
FD
Ccr
Level
LM
von
143
diagrams
Surprisingly
definite
MSD
msec
Foundation
(R)-
Tumour
long‐term
irbesartan
attenuate
340
Pi
q24h
evaporator
focusing
Ab
pm
recrudescence
antituberculosis
antagonistic
48-h
polarity
serine
circumstances
151
1.19
Internal
1990
oils
H&E
committees
138
venetoclax
isotonic
boards
BRAF
prompted
geriatric
arrival
incubating
DAT
non-obese
outlier
rFVIII
microenvironment
NSC
parenchyma
expressions
dose-ranging
17.4
dihydrogen
PCP
Soluplus
cytomegalovirus
capsaicin
CLINICAL
phage
urate
ml–1
telaprevir
lesinurad
teriparatide
DLBCL
favor
Guideline
chromatographed
malnutrition
cefpodoxime
Modified
Ultra
Microdialysis
Induction
RAL
mg/Kg
lipopolysaccharide
repolarization
LAmB
nephrotoxic
cinacalcet
expectation
Carlsbad
spectrophotometry
PHARMACOLOGY
gadolinium
macitentan
normality
alendronate
Summary
dipeptidyl
SCIEX
hemodynamics
subchronic
derivatized
nephropathy
junction
School
wogonin
constituted
IU/L
Digoxin
methylated
pancreatitis
cycling
PXRD
ARC
polyphenol
experiences
16.2
hydrated
amplified
P<0.0001
OCA
Rc
Q3W
OXC
bacteriostatic
flow-rate
R&D
mammals
cooling
CFU/ml
dose-independent
immersed
name
1.37
ULOQ
conduction
firstly
ml/h
µg/L
unnecessary
thiamine
Blank
oily
suramin
deltoid
hypoglycaemia
pups
easier
references
bi-exponential
sheath
propensity
Intranasal
ZP
1.31
1h
hyperlipidemia
proceeded
mesh
monomeric
dropwise
CAR
129
allometry
APC
pethidine
biweekly
nose
1.36
epoxide
THF
RS
BMD
placebo‐controlled
inpatients
rectally
Skin
Lipid
Regardless
influential
painful
attack
glucocorticoids
two‐compartment
mV.
TXA
coordination
17.1
cefixime
replace
harmonic
ICA
tremor
carbonyl
156
exactly
Red
p.m.
10-day
EudraCT
IF
prazosin
CLp
programme
communication
ve
Lastly
Bone
short-acting
fabricated
16.9
nanostructured
ANP
Guidance
UA
protons
proteolytic
DR
modality
trigger
bounds
mildly
immunoreactivity
stereoisomers
QUE
mesenteric
Veterinary
n=4
P-value
dinner
19.0
Unbound
loads
MgCl2
biology
aspergillosis
opened
FPG
two-sequence
ZnO
Cockcroft-Gault
Instead
flushing
microflora
metric
lipid-based
transcriptional
integrase
raloxifene
2c
lives
biotinylated
gelation
5-mg
ADD
NG
raise
d-amphetamine
1:10
1.48
chromogenic
Ethanol
volumetric
17.3
stereoselectivity
12-week
pirfenidone
truncated
within-day
bacteremia
anti-mouse
HT-29
PSMA
boundary
effect-site
overweight
descriptively
regime
141
cholestasis
rhG-CSF
commencement
Examination
impair
devoid
glucuronic
≥30
transduction
linking
NASH
CYP3A5*1
hollow
half-maximal
PNA
Diagnostic
victim
automatically
17.2
275
stearate
AZA
1.42
electrolytes
foot
cefadroxil
functionally
≥5
childbearing
18.4
Jolla
AND
IIa
antimicrobials
10th
Organ
LC-MS-MS
Triton
0–2
20,000
neuroendocrine
patent
cytoplasm
abatacept
2-way
Aurora
Ministry
movements
osteoarthritis
abolished
larvae
pumped
abstinence
1:4
zonisamide
constitute
lymphopenia
inappropriate
revealing
text
repeatability
19.5
doxazosin
RF
Instrument
shapes
controversial
substitute
pM
sulphoxide
copies
hardly
1/*1
P1
run-in
stabilities
granule
gap
pocket
low-
embolism
unpredictable
ensured
bleeds
freezer
declared
continuation
mutated
norfluoxetine
Balb/c
attacks
Danshen
exponents
transmembrane
palliative
Kaplan
Unchanged
Al
siponimod
Few
seed
IFN-γ
glucagon-like
diuretics
macromolecules
38.5
P2Y12
ontogeny
fundamental
caspase
distribute
Covariate
DMXAA
conformed
pindolol
UGT1A1*28
denotes
addiction
chewable
dialyzed
reacted
butorphanol
character
probucol
DSS
Liking
ATR
triggered
programmed
piperacillin/tazobactam
pramipexole
microorganisms
Experiment
clinics
mares
MDR-TB
arise
palonosetron
competing
GM-CSF
TAF
permits
DETERx
came
viz
bleomycin
6-hour
Sorafenib
solutes
CFR
ln
destruction
Qiagen
substituents
DHE
kg–1
evolocumab
euthanasia
mug/ml
concentrates
ground
nateglinide
HIV-positive
rate-limiting
SVR
evenly
extravasation
K(i
clarified
besides
proof-of-concept
bronchitis
Interactions
ginger
permeated
two-compartmental
encephalopathy
Twenty-two
sensitization
24-hr
empiric
OP
continues
face
Exploratory
80:20
facilities
helped
LZD
FS
Up
Fentanyl
excretory
daratumumab
discriminate
Cisplatin
BL
EXE
manganese
chewing
away
bar
phthalate
overview
1-5
antiinflammatory
hypothyroidism
PKQuest
181
rectum
111In
colonies
40.0
construction
anti
aliskiren
blasts
schizophrenic
fibers
consciousness
tamsulosin
comparability
aceclofenac
overexpressed
fibroblast
kcal
hearing
pegfilgrastim
luteolin
1.47
nutrient
innovative
TBA
dasabuvir
OGTT
7A
boron
cannabinoid
File
loose
HSYA
flare
DH
quartile
post-infusion
600-mg
observable
t-tests
DHC
appearing
two-treatment
Sampling
ensuring
chrysin
ICP-MS
triple-quadrupole
21.4
meperidine
G.
Gibco
partner
1640
GTN
Corp
Imatinib
immunity
CT-P13
0.014
Fructus
dimer
retrieved
thymidine
your
325
Stereoselective
Promega
1250
convert
Secondly
homogenizer
aware
MgSO4
I.V.
flucloxacillin
STAT3
Lewis
scope
unadjusted
CSL112
Throughout
serves
DOES
buffers
Gastric
flank
5500
IFN-alpha
LCMS
j
LN
nicotinamide
department
PKPD
escape
VKORC1
levobupivacaine
functioning
nebulized
bags
176
intent-to-treat
anti-VEGF
CYP3A4*22
HEK293
Dunnett
sandwich
speculate
Severity
Twenty-three
TNF-alpha
Han
Green
28.6
Gemcitabine
1-year
combine
jet
optimised
photodynamic
AUC0→∞
Meier
vitro/in
superficial
18.6
brown
fortified
concordance
TH
massive
students
Ellicott
isoenzyme
SLS
microM.
30-mg
mediators
authorities
AUMC
GIR
branded
Antitumor
items
characterise
HPLC-grade
hippocampal
taxanes
maintains
dendrimers
transplants
cefaclor
Genotyping
antacids
L-DOPA
assembly
imputed
liter/kg
plants
macromolecular
London
Org
dodecyl
milrinone
isopropyl
element
acetylator
glasdegib
<3
Voriconazole
clinician
14C-labeled
14,000
1989
What
treatment‐related
atrophy
GFJ
pre-specified
ABT
